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HETEROARYL INHIBITORS OF PAD4
BACKGROUND OF THE INVENTION
[0001] PAD4 is a member of the peptidylarginine deiminase (PAD) family of enzymes
capable of catalysing the citrullination of arginine into citrulline within peptide sequences.
PAD4 is responsible for the deimination or citrullination of a variety of proteins in vitro and in
vivo, with consequences of diverse functional responses in a variety of diseases (Jones J.E. et al,
Curr. Opin. Drug Discov. Devel., 12(5), (2009),616-627). Examples of exemplar diseases
include rheumatoid arthritis, diseases with neutrophilic contributions to pathogenesis (for
example vasculitis, systemic lupus erythematosus, ulcerative colitis) in addition to oncology
indications. PAD4 inhibitors also have wider applicability as tools and therapeutics for human
disease through epigenetic mechanisms.
[0002] Inhibitors of PAD4 have utility against Rheumatoid Arthritis (RA). RA is an auto-
immune disease affecting approximately 1% of the population (Wegner N. et al, Immunol. Rev.,
233(1) (2010), 34-54). It is characterised by inflammation of articular joints leading to
debilitating destruction of bone and cartilage. A weak genetic association between PAD4
polymorphisms and susceptibility to RA has been suggested, albeit inconsistently, in a number of
population studies (Kochi Y. et al, Ann. Rheum. Dis., 70, (2011),512-515). PAD4 (along with
family member PAD2) has been detected in synovial tissue where it is responsible for the
deimination of a variety of joint proteins. This process is presumed to lead to a break of
tolerance to, and initiation of immune responses to, citrullinated substrates such as fibrinogen,
vimentin and collagen in RA joints. These anti-citrullinated protein antibodies (ACPA)
contribute to disease pathogenesis and may also be used as a diagnostic test for RA (e.g. the
commercially available CCP2 or cyclic citrullinated protein 2 test). In addition, increased
citrullination may also offer additional direct contributions to disease pathogenesis through its
ability to affect directly the function of several joint and inflammatory mediators (e.g. fibrinogen,
anti-thrombin, multiple chemokines). In a smaller subset of RA patients, anti-PAD4 antibodies
can be measured and may correlate with a more erosive form of the disease.
[0003] PAD4 inhibitors are also useful for the reduction of pathological neutrophil activity in
a variety of diseases. Studies suggest that the process of Neutrophil Extracellular Trap (NET)
formation, an innate defence mechanism by which neutrophils are able to immobilise and kill
pathogens, is associated with histone citrulllination and is deficient in PAD4 knockout mice
(Neeli I. et al, J. Immunol., 180, (2008), 1895-1902 and Li P. et al, J. Exp. Med., 207(9), (2010),
1853-1862). PAD4 inhibitors may therefore have applicability for diseases where NET
formation in tissues contributes to local injury and disease pathology. Such diseases include, but
are not limited to, small vessel vasculitis (Kessenbrock K. et al, Nat. Med., 15(6), (2009), 623-
625), systemic lupus erythematosus (Hakkim A. et al, Proc. Natl. Acad. Sci. USA, 107(21),
(2010), 9813-9818 and Villanueva E. et al, J. Immunol., 187(1), (2011), 538-52), ulcerative
colitis (Savchenko A. et al, Pathol. Int., 61(5), (2011), 290-7), cystic fibrosis, asthma (Dworski R.
et al, J. Allergy Clin. Immunol., 127(5), (2011), 1260-6), deep vein thrombosis (Fuchs T. et al,
Proc. Natl. Acad. Sci. USA, 107(36), (2010), 15880-5), periodontitis (Vitkov L. et al,
Ultrastructural Pathol., 34(1), (2010), 25-30), sepsis (Clark S.R. et al, Nat. Med., 13(4), (2007),
463-9), appendicitis (Brinkmann V. et al, Science, 303, (2004), 1532-5), and stroke. In addition,
there is evidence that NETs may contribute to pathology in diseases affecting the skin, eg in
cutaneous lupus erythematosis (Villanueva E. et al, J. Immunol., 187(1), (2011), 538-52) and
psoriasis (Lin A.M. et al., J. Immunol., 187(1), (2011), 490-500), so a PAD4 inhibitor may show
benefit to tackle NET skin diseases, when administered by a systemic or cutaneous route. PAD4
inhibitors may affect additional functions within neutrophils and have wider applicability to
neutrophilic diseases.
[0004] Studies have demonstrated efficacy of tool PAD inhibitors (for example chloro-
amidine) in a number of animal models of disease, including collagen-induced arthritis (Willis
V.C. et al, J. Immunol., 186(7), (2011), 4396-4404), dextran sulfate sodium (DSS)-induced
experimental colitis (Chumanevich A.A. et al, Am. J. Physiol. Gastrointest. Liver Physiol.,
300(6), (2011), G929–G938), spinal cord repair (Lange S. et al, Dev. Biol., 355(2), (2011), 205-
14), and experimental autoimmune encephalomyelitis (EAE). The DSS colitis report also
demonstrates that chloro-amidine drives apoptosis of inflammatory cells both in vitro and in
vivo, suggesting that PAD4 inhibitors may be effective more generally in widespread
inflammatory diseases.
[0005] PAD4 inhibitors are also useful in the treatment of cancers (Slack.J.L. et al, Cell. Mol.
Life Sci., 68(4), (2011), 709-720). Over-expression of PAD4 has been demonstrated in
numerous cancers (Chang X. et al, BMC Cancer, 9, (2009), 40). An anti-proliferative role has
been suggested for PAD4 inhibitors from the observation that PAD4 citrullinates arginine
residues in histones at the promoters of p53-target genes such as p21, which are involved in cell
cycle arrest and induction of apoptosis (Li P. et al, Mol. Cell Biol., 28(15), (2008), 4745-4758).
[0006] The aforementioned role of PAD4 in deiminating arginine residues in histones may
be indicative of a role for PAD4 in epigenetic regulation of gene expression. PAD4 is the
primary PAD family member observed to be resident in the nucleus as well as the cytoplasm.
Early evidence that PAD4 may act as a histone demethyliminase as well as a deiminase is
inconsistent and unproven. However, it may reduce histone arginine methylation (and hence
epigenetic regulation associated with this mark) indirectly via depletion of available arginine
residues by conversion to citrulline. PAD4 inhibitors are useful as epigenetic tools or
therapeutics for affecting expression of varied target genes in additional disease settings.
Through such mechanisms, PAD4 inhibitors may also be effective in controlling citrullination
levels in stem cells and may therefore therapeutically affect the pluripotency status and
differentiation potential of diverse stem cells including, but not limited to, embryonic stem cells,
neural stem cells, haematopoietic stem cells and cancer stem cells. Accordingly, there remains
an unmet need to identify and develop PAD4 inhibitors for the treatment of PAD4-mediated
disorders.
SUMMARY OF THE INVENTION
[0007] It has now been found that compounds of formula I are useful as inhibitors of PAD4:
or a pharmaceutically acceptable salt thereof, wherein each of Ring A, Ring B, R1, R2, R3, X1 ,L,
and R4 is as defined and described herein.
[0008] It has also been found that com ounds of formula I’ are useful as inhibitors of PAD4:
or a pharmaceutically acceptable salt thereof, wherein each of Ring A, Ring B, R1 , R2, R3, X1,L,
R4 and n is as defined and described herein.
[0009] In some embodiments, a provided compound demonstrates selectivity for PAD4 with
respect to PAD2. The present invention also provides pharmaceutically acceptable compositions
comprising a provided compound. Provided compounds are useful in treatment of various
disorders associated with PAD4. Such disorders are described in detail, herein, and include, for
example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer,
cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.
DETAILED DESCRIPTION OF THE INVENTION
1. General Description of Certain Aspects of the Invention
[0010] In some embodiments, such compounds include those of the formulae described
herein, or a pharmaceutically acceptable salt thereof, wherein each variable is as defined herein
and described in embodiments. Such compounds have the structure of formula I:
I
or a pharmaceutically acceptable salt thereof, wherein:
Rin A is
wherein Ring A is optionally substituted with 1-4 groups selected from fluorine, -CN, -OR,
or C1-6 aliphatic optionally substituted with 1-3 fluorine atoms;
Ring B is a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from
nitrogen, oxygen, or sulfur.;
R 1 is hydrogen, -Cy, or C1-6 aliphatic optionally substituted with –Cy and optionally further
substituted with 1-4 groups selected from fluorine, -CN, or -OR;
each -Cy is independently 4-7 membered saturated monocyclic ring having 0-2 heteroatoms
independently selected from nitrogen, oxygen, or sulphur, wherein –Cy is optionally
substituted with 1-4 groups selected from fluorine, -CN, or -OR;
R 2 is hydrogen, -CN, -OR, -Cy, or C1-10 aliphatic optionally substituted with –Cy and optionally
further substituted with 1-5 groups selected from fluorine, –CN, or –OR;
X 1 is N or C(R 3 );
R 3 is –R or –OR;
each R is independently hydrogen or C1-6 aliphatic optionally substituted with 1-3 fluorine
atoms;
L is selected from a covalent bond or a C1-6 membered straight or branched, saturated or
unsaturated hydrocarbon chain wherein one methylene unit of L is optionally replaced by –
C(O)N(R y)-, wherein R y is R or –CH 2 phenyl; and
R 4 is halogen, R, phenyl, or a 5-6-membered heteroaryl ring having 1-3 heteroatoms
independently selected from nitrogen, oxygen, or sulphur, wherein R4 is optionally
substituted with 1-4 groups independently selected from halogen, -CN, -OR, or C1-6 aliphatic
optionally substituted with 1-3 fluorine atoms
[0011] In some embodiments, such compounds include those of the formulae described
herein, or a pharmaceutically acceptable salt thereof, wherein each variable is as defined herein
and described in embodiments. Such compounds have the structure of formula I’:
I’
or a pharmaceutically acceptable salt thereof, wherein:
Rin
4 groups selected from fluorine, -CN, -OR, or C1-6 aliphatic optionally substituted with 1-3
fluorine atoms;
Ring B is a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from
nitrogen, oxygen, or sulfur;
R1 is hydrogen, -Cy, or C1-6 aliphatic optionally substituted with –Cy and optionally further
substituted with 1-4 groups selected from fluorine, -CN, or -OR;
each -Cy is independently a 6-membered aryl ring containing 0-2 nitrogen atoms, or a 4-7
membered saturated monocyclic ring having 0-2 heteroatoms independently selected from
nitrogen, oxygen, or sulphur, wherein –Cy is optionally substituted with 1-4 groups selected
from fluorine, -CN, or -OR;
R2 is hydrogen, -CN, -OR, -Cy, or C1-10 aliphatic optionally substituted with –Cy and optionally
further substituted with 1-5 groups selected from fluorine, –CN, or –OR; or:
two R2 groups on the same carbon atom are optionally taken together to form =O;
n is 1, 2, or 3;
X 1 is N or C(R 3 );
R3 is –R, halogen, or –OR;
each R is independently hydrogen or C1-6 aliphatic optionally substituted with 1-3 fluorine
atoms;
L is selected from a covalent bond or a C1-6 membered straight or branched, saturated or
unsaturated hydrocarbon chain wherein one methylene unit of L is optionally replaced by –
S(O) 2 – or –C(O)N(R y )-, wherein Ry is R or –CH 2 phenyl; and
R4 is halogen, R, phenyl, or a 5-6-membered heteroaryl ring having 1-3 heteroatoms
independently selected from nitrogen, oxygen, or sulphur, wherein R4 is optionally
substituted with 1-4 groups independently selected from halogen, -CN, -OR, -C(O)OH, or C1 -
6 aliphatic optionally substituted with 1-3 fluorine atoms.
2. Definitions
[0012] Compounds of the present invention include those described generally herein, and are
further illustrated by the classes, subclasses, and species disclosed herein. As used herein, the
following definitions shall apply unless otherwise indicated. For purposes of this invention, the
chemical elements are identified in accordance with the Periodic Table of the Elements, CAS
version, Handbook of Chemistry and Physics, 75 th Ed. Additionally, general principles of
organic chemistry are described in “Organic Chemistry”, Thomas Sorrell, University Science
Books, Sausalito: 1999, and “March’s Advanced Organic Chemistry”, 5t h Ed., Ed.: Smith, M.B.
and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby
incorporated by reference.
[0013] The term “aliphatic” or “aliphatic group”, as used herein, means a straight-chain (i.e.,
unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely
saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or
bicyclic hydrocarbon that is completely saturated or that contains one or more units of
unsaturation, but which is not aromatic (also referred to herein as "carbocycle," “cycloaliphatic”
or “cycloalkyl”), that has a single point of attachment to the rest of the molecule. Unless
otherwise specified, aliphatic groups contain 1-6 aliphatic carbon atoms. In some embodiments,
aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic groups
contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3
aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic
carbon atoms. In some embodiments, “cycloaliphatic” (or “carbocycle” or “cycloalkyl”) refers
to a monocyclic C3-C6 hydrocarbon that is completely saturated or that contains one or more
units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest
of the molecule. Suitable aliphatic groups include, but are not limited to, linear or branched,
substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as
(cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
[0014] As used herein, the term "pharmaceutically acceptable salt" refers to those salts which
are, within the scope of sound medical judgment, suitable for use in contact with the tissues of
humans and lower animals without undue toxicity, irritation, allergic response and the like, and
are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well
known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in
detail in J. Pharmaceutical Sciences, 1977, 66, 1–19, incorporated herein by reference.
Pharmaceutically acceptable salts of the compounds of this invention include those derived from
suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable,
nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as
hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with
organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid
or malonic acid or by using other methods used in the art such as ion exchange. Other
pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate,
benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate,
cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate,
glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide,
2–hydroxy–ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate,
malonate, methanesulfonate, 2–naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate,
palmitate, pamoate, pectinate, persulfate, 3–phenylpropionate, phosphate, pivalate, propionate,
stearate, succinate, sulfate, tartrate, thiocyanate, p–toluenesulfonate, undecanoate, valerate salts,
and the like.
[0015] Salts derived from appropriate bases include alkali metal, alkaline earth metal,
ammonium and salts. Representative alkali or alkaline earth metal salts include
sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically
acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and
amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate,
phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
[0016] Unless otherwise stated, structures depicted herein are also meant to include all
isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the
structure; for example, the R and S configurations for each asymmetric center, Z and E double
bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as
well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present
compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms
of the compounds of the invention are within the scope of the invention. Additionally, unless
otherwise stated, structures depicted herein are also meant to include compounds that differ only
in the presence of one or more isotopically enriched atoms. For example, compounds having the
present structures including the replacement of hydrogen by deuterium or tritium, or the
replacement of a carbon by a 1 3C- or 1 4C-enriched carbon are within the scope of this invention.
Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as
therapeutic agents in accordance with the present invention.
[0017] The terms “measurable affinity” and “measurably inhibit,” as used herein, means a
measurable change in PAD4 activity between a sample comprising a compound of the present
invention, or composition thereof, and PAD4, and an equivalent sample comprising PAD4 in the
absence of said compound, or composition thereof.
3. Description of Exemplary Compounds
[0018] According to one aspect, the present invention provides a compound of formula I:
I
or a pharmaceutically acceptable salt thereof, wherein:
Rin A is
wherein Ring A is optionally substituted with 1-4 groups selected from fluorine, -CN, -OR,
or C1-6 aliphatic optionally substituted with 1-3 fluorine atoms;
Ring B is a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from
nitrogen, oxygen, or sulfur.;
R1 is hydrogen, -Cy, or C1-6 aliphatic optionally substituted with –Cy and optionally further
substituted with 1-4 groups selected from fluorine, -CN, or -OR;
each -Cy is independently 4-7 membered saturated monocyclic ring having 0-2 heteroatoms
independently selected from nitrogen, oxygen, or sulphur, wherein –Cy is optionally
substituted with 1-4 groups selected from fluorine, -CN, or -OR;
R2 is hydrogen, -CN, -OR, -Cy, or C1-10 aliphatic optionally substituted with –Cy and optionally
further substituted with 1-5 groups selected from fluorine, –CN, or –OR;
X 1 is N or C(R 3 );
R3 is –R or –OR;
each R is independently hydrogen or C1-6 aliphatic optionally substituted with 1-3 fluorine
atoms;
L is selected from a covalent bond or a C1-6 membered straight or branched, saturated or
unsaturated hydrocarbon chain wherein one methylene unit of L is optionally replaced by –
C(O)N(R y)-, wherein Ry is R or –CH2phenyl; and
R4 is halogen, R, phenyl, or a 5-6-membered heteroaryl ring having 1-3 heteroatoms
independently selected from nitrogen, oxygen, or sulphur, wherein R4 is optionally
substituted with 1-4 groups independently selected from halogen, -CN, -OR, C1-6 aliphatic
optionally substituted with 1-3 fluorine atoms.
[0019] According to another aspect, the present invention provides a compound of formula I’:
I’
or a pharmaceutically acceptable salt thereof, wherein:
Rin A is
4 groups selected from fluorine, -CN, -OR, or C1-6 aliphatic optionally substituted with 1-3
fluorine atoms;
Ring B is a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from
nitrogen, oxygen, or sulfur;
R 1 is hydrogen, -Cy, or C1-6 aliphatic optionally substituted with –Cy and optionally further
substituted with 1-4 groups selected from fluorine, -CN, or -OR;
each -Cy is independently a 6-membered aryl ring containing 0-2 nitrogen atoms, or a 4-7
membered saturated monocyclic ring having 0-2 heteroatoms independently selected from
nitrogen, oxygen, or sulphur, wherein –Cy is optionally substituted with 1-4 groups selected
from fluorine, -CN, or -OR;
R 2 is hydrogen, -CN, -OR, -Cy, or C1-10 aliphatic optionally substituted with –Cy and optionally
further substituted with 1-5 groups selected from fluorine, –CN, or –OR; or:
two R 2 groups on the same carbon atom are optionally taken together to form =O;
n is 1, 2, or 3;
X 1 is N or C(R 3 );
R 3 is –R, halogen, or –OR;
each R is independently hydrogen or C1-6 aliphatic optionally substituted with 1-3 fluorine
atoms;
L is selected from a covalent bond or a C1-6 membered straight or branched, saturated or
unsaturated hydrocarbon chain wherein one methylene unit of L is optionally replaced by –
S(O) 2 – or –C(O)N(R y )-, wherein Ry is R or –CH 2 phenyl; and
R4 is halogen, R, phenyl, or a 5-6-membered heteroaryl ring having 1-3 heteroatoms
independently selected from nitrogen, oxygen, or sulphur, wherein R4 is optionally
substituted with 1-4 groups independently selected from halogen, -CN, -OR, -C(O)OH, or C1 -
6 aliphatic optionally substituted with 1-3 fluorine atoms.
[0020] As defined above, X1 is N or C(R 3 ). In some embodiments, X 1 is N. In some
embodiments, X1 is C(R 3 ). In certain embodiments, the present invention provides a compound
formula I-a or I-b:
I-a I-b
or a pharmaceutically acceptable salt thereof, wherein each of Ring A, Ring B, R1 , R2 , R3 , L, and
R4 is as defined and described herein.
[0021] In certain embodiments, the present invention provides a compound of formula I’-a
I’-b:
I’-a I’-b
or a pharmaceutically acceptable salt thereof, wherein each of Ring A, Ring B, R1 , R2 , R3 , L, R4
and n is as defined and described herein.
[0022] As defined above and described herein, R1 is hydrogen, -Cy, or C1-6 aliphatic
optionally substituted with –Cy and optionally further substituted with 1-4 groups selected from
fluorine, -CN, or -OR; each -Cy is independently 4-7 membered saturated monocyclic ring
having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulphur, wherein –Cy
is optionally substituted with 1-4 groups selected from fluorine, -CN, or –OR.
[0023] In some embodiments, R1 is hydrogen. In some embodiments, R1 is –Cy. In some
embodiments, R1 is C1-6 aliphatic optionally substituted with 1-4 groups selected from fluorine, -
CN, or -OR. In some embodiments, R1 is C1-3 aliphatic. In some embodiments, R1 is methyl. In
some embodiments, R1 is ethyl. In some embodiments, R1 is propyl. In some embodiments, R1
is –CH 2 -cyclobutyl optionally substituted with methyl and –OH. In some embodiments, each-Cy
is independently a 4-7 membered saturated monocyclic ring having 0-2 heteroatoms
independently selected from nitrogen, oxygen or sulphur. In some embodiments, -Cy is
optionally substituted with 1-4 groups selected from fluorine, -CN, or –OR. In some
embodiments, -Cy is phenyl. In some embodiments, -Cy is pyridyl.
[0024] In some embodiments, -Cy is a 6-membered aryl ring containing 0-2 nitrogen atoms.
[0026] As defined above and described herein, R2 is hydrogen, -CN, -OR, -Cy, or C1-10
aliphatic optionally substituted with –Cy and optionally further substituted with 1-5 groups
selected from fluorine, –CN, or –OR. In some embodiments, R2 is hydrogen. In some
embodiments, R2 is C1-10 aliphatic optionally substituted with 1-5 groups selected from fluorine,
–CN, or -OR. In some embodiments, R2 is C1-10 aliphatic optionally substituted with –Cy and
optionally further substituted with 1-5 groups selected from fluorine, -CN, or –OR. In some
embodiments, R2 is –Cy. In some embodiments, R2 is methyl. In some embodiments, R2 is
ethyl. In some embodiments, R2 is propyl. In some embodiments, R 2 is butyl. In some
embodiments, R2 is pentyl. In some embodiments, R2 is hexyl. In some embodiments, R2 is
cyclopropyl. In some embodiments, R2 is cyclobutyl. In some embodiments, R2 is cyclopentyl.
In some embodiments, R 2 is cyclohexyl. In some embodiments, R2 is cyclopropylmethyl. In
some embodiments, R2 is cyclobutylmethyl. In some embodiments, R2 is cyclopentylmethyl. In
some embodiments, R2 is cyclohexylmethyl. In some embodiments, R2 is cyclopropylethyl. In
some embodiments, R 2 is cyclobutylethyl. In some embodiments, R 2 is cyclopentylethyl. In
some embodiments, R2 is cyclohexylethyl. In some embodiments, R2 is –CH2-cyclopropyl or –
CH2 -cyclobutyl. In some embodiments, R
1 is –CH 2 -cyclobutyl optionally substituted with
methyl and –OH. In some embodiments, R1 is selected from those depicted in Table 1, below.
[0027] In some embodiments, R 2 is C1-10 aliphatic, substituted with 1-5 fluorine atoms. In
some embodiments, R2 is C1-10 aliphatic, substituted with 1-5 fluorine atoms. In some
embodiments, R2 is C 1-10 aliphatic, substituted with 1 fluorine atom. In some embodiments, R
2 is
C1-10 aliphatic, substituted with 2 fluorine atoms. In some embodiments, R2 is C1-10 aliphatic,
substituted with 3 fluorine atoms. In some embodiments, R 2 is C1-10 aliphatic, substituted with 4
fluorine atoms. In some embodiments, R 2 is C 1-10 aliphatic, substituted with 5 fluorine atoms. In
some embodiments, R2 is methyl, substituted with 1-3 fluorine atoms. In some embodiments, R2
is trifluoromethyl. In some embodiments, R2 is ethyl, substituted with 1-5 fluorine atoms. In
some embodiments, R2 is 2,2,2-trifluoroethyl. In some embodiments, R2 is propyl, substituted
with 1-5 fluorine atoms. In some embodiments, R2 is 3,3,3-trifluoropropyl. In some
embodiments, R 2 is butyl, substituted with 1-5 fluorine atoms. In some embodiments, R2 is
4,4,4-trifluorobutyl. In some embodiments, R2 is pentyl, substituted with 1-5 fluorine atoms. In
some embodiments, R2 is 5,5,5-trifluoropentyl. In some embodiments, R 2 is hexyl, substituted
with 1-5 fluorine atoms. In some embodiments, R2 is 6,6,6-trifluorohexyl. In some
embodiments, R 2 is selected from those depicted in Table 1, below.
[0028] In some embodiments, R 2 is phenyl. In some embodiments, R 2 is n-propyl. In some
embodiments, R2 is iso-propyl. In some embodiments, R2 is pyridyl. In some embodiments, R2
is fluoro. In some embodiments, R 2 is bromo. In some embodiments, R 2 is benzyl. In some
embodiments, R 2 is –Ome. In some embodiments, R2 is –OH. In some embodiments, R2 is –
CN. In some embodiments, two R2 groups are taken together to form =O.
[0032] As defined above and described herein, R3 is –R or –OR. In some embodiments, R3
is hydrogen. In some embodiments, R3 is C1-6 aliphatic optionally substituted with 1-3 fluorine
atoms. In some embodiments, R3 is –OCH3. In some embodiments, R3 is selected from those
depicted in Table 1, below.
[0033] In some embodiments, R3 is halogen. In some embodiments, R3 is fluoro.
[0034] As defined above, Ring A is
In some embodiments, Ring A is selected from those depicted in Table 1, below.
[0038] In some embodiments, Ring B is a 5-membered heteroaryl ring having 1-3
heteroatoms independently selected from nitrogen, oxygen, or sulfur. In other embodiments,
Ring B is a 6-membered heteroaryl ring having 1-2 nitrogens.
[0039] In some embodiments, Ring B is imidazolyl, pyrazolyl, pyrrolyl, pyridyl, or thiazolyl.
In some embodiments, Ring B is imidazolyl, pyrazolyl, pyrrolyl, or thiazolyl. In some
embodiments, Ring B is pyridyl. In some embodiments, Ring B is selected from those depicted
in Table 1, below.
[0040] In some embodiments, Ring B is pyrrolyl. In some embodiments, Ring B is
bodiments, Ring B is imidazolyl. In some embodiments, Ring B is
[0042] In some embodiments, Ring B is phenylenyl. In some embodiments, Ring B is
pyridonenyl. In some embodiments, Ring B is pyridinyl. In some embodiments, Ring B is
pyrrolenyl. In some embodiments, Ring B is pyazolenyl. In some embodiments, Ring B is
thiazolenyl.
[0043] In some embodiments, Ring B with its R2 and –L-R4 substituents is . In
some embodiments, Ring B with its R2 and –L-R4 . In some
embodiments, Ring B with its R2 and –L-R4 substituents is
.
In some
embodiments, Ring B with its R2 and –L-R4 substituents is . In some
embodiments, Ring B with its R2 and –L-R4 substituents is . In some
embodiments, Ring B with its
Ring B with its R2 and –L-R4












[0048] As defined above and described herein, L is selected from a covalent bond or a C1-6
membered straight or branched, saturated or unsaturated hydrocarbon chain wherein one
methylene unit of L is optionally replaced by –C(O)N(R y )-, wherein R y is R or –CH 2phenyl. In
some embodiments, L is a covalent bond. In some embodiments, L is –(CH2)-. In some
embodiments, L is -C(O)N(R y)-. In some embodiments, R y is R. In some embodiments, Ry is
hydrogen. In some embodiments, Ry is C1-6 aliphatic optionally substituted with 1-3 fluorine
atoms. In some embodiments, Ry is –CH2phenyl. In some embodiments, -L- is selected from
those depicted in Table 1, below.
[0049] In some embodiments, L is a C1-6 membered straight or branched, saturated or
unsaturated hydrocarbon chain wherein one methylene unit of L is optionally replaced by –
S(O)2–. In some embodiments, L is –S(O)2-. In some embodiments, L is –CH2CH2-.
[0051] As defined above and described herein, R4 is halogen, R, phenyl, or a 5-6-membered
heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or
sulphur, wherein R4 is optionally substituted with 1-4 groups independently selected from
halogen, -CN, -OR, or C1-6 aliphatic optionally substituted with 1-3 fluorine atoms.
[0052] In some embodiments, R4 is halogen. In some embodiments, R4 is –Br. In some
embodiments, R4 is cyano. In some embodiments, R4 is phenyl. In some embodiments, R4 is
pyridyl. In some embodiments, R4 is a 5-6 membered heteroaryl ring having 1-3 heteroatoms
independently selected from nitrogen, oxygen or sulphur, wherein R4 is optionally substituted
with 1-4 groups independently selected from halogen, -CN, -OR, or C1-6 aliphatic optionally
substituted with 1-3 fluorine atoms. In some embodiments, R4 is selected from those depicted in
Table 1, below.
[0053] In some embodiments, R4 is substituted with -C(O)OH.
[0054] In some embodiments, R 4 is methyl. In some embodiments, R4 is ethyl. In some
embodiments, R4 is hydrogen. In some embodiments, R4 is cyclopropyl. In some embodiments,
R4 is cyclobutyl. In some embodiments, R4 is n-propyl. In some embodiments, R4 is iso-propyl.
In some embodiments, R4 is fluoro.
e is .
[0058] As defined above and described herein, n is 1, 2, or 3. In some embodiments, n is 1.
In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is selected
from those depicted in Table 1, below.
[0059] In some embodiments, the compound of formula I or formula I’ is selected from
those depicted below in Table 1.













[0060] In certain embodiments, the present invention provides any compound described
above and herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the
present invention provides a compound as depicted in Table 1, above, or a pharmaceutically
acceptable salt thereof.
[0061] In some embodiments, the present invention provides any compound described above
and herein in isolated form.
4. Uses, Formulation and Administration
Pharmaceutically acceptable compositions
[0062] According to another embodiment, the invention provides a composition comprising
a compound of this invention or a pharmaceutically acceptable derivative thereof and a
pharmaceutically acceptable carrier, adjuvant, or vehicle. The amount of compound in
compositions of this invention is such that is effective to measurably inhibit PAD4, in a
biological sample or in a patient. In certain embodiments, the amount of compound in
compositions of this invention is such that is effective to measurably inhibit PAD4, in a
biological sample or in a patient. In certain embodiments, a composition of this invention is
formulated for administration to a patient in need of such composition. In some embodiments, a
composition of this invention is formulated for oral administration to a patient.
[0063] The term “subject,” as used herein, is used interchangeably with the term “patient”
and means an animal, preferably a mammal. In some embodiments, a subject or patient is a
human. In other embodiments, a subject (or patient) is a veterinary subject (or patient). In some
embodiments, a veterinary subject (or patient) is a canine, a feline, or an equine subject.
[0064] The term “pharmaceutically acceptable carrier, adjuvant, or vehicle” refers to a non-
toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the
compound with which it is formulated. Pharmaceutically acceptable carriers, adjuvants or
vehicles that may be used in the compositions of this invention include, but are not limited to,
ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum
albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial
glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as
protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium
chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based
substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes,
polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
[0065] Compositions of the present invention may be administered orally, parenterally, by
inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-
articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial
injection or infusion techniques. Preferably, the compositions are administered orally,
intraperitoneally or intravenously. Sterile injectable forms of the compositions of this invention
may be aqueous or oleaginous suspension. These suspensions may be formulated according to
techniques known in the art using suitable dispersing or wetting agents and suspending agents.
The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-
toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution
and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally
employed as a solvent or suspending medium.
[0066] For this purpose, any bland fixed oil may be employed including synthetic mono- or
di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the
preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or
castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may
also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or
similar dispersing agents that are commonly used in the formulation of pharmaceutically
acceptable dosage forms including emulsions and suspensions. Other commonly used
surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers
which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or
other dosage forms may also be used for the purposes of formulation.
[0067] Pharmaceutically acceptable compositions of this invention may be orally
administered in any orally acceptable dosage form including, but not limited to, capsules, tablets,
aqueous suspensions or solutions. In the case of tablets for oral use, carriers commonly used
include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also
typically added. For oral administration in a capsule form, useful diluents include lactose and
dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is
combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or
coloring agents may also be added.
[0068] Alternatively, pharmaceutically acceptable compositions of this invention may be
administered in the form of suppositories for rectal administration. These can be prepared by
mixing the agent with a suitable non-irritating excipient that is solid at room temperature but
liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such
materials include cocoa butter, beeswax and polyethylene glycols.
[0069] Pharmaceutically acceptable compositions of this invention may also be administered
topically, especially when the target of treatment includes areas or organs readily accessible by
topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable
topical formulations are readily prepared for each of these areas or organs.
[0070] Topical application for the lower intestinal tract can be effected in a rectal
suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal
patches may also be used.
[0071] For topical applications, provided pharmaceutically acceptable compositions may be
formulated in a suitable ointment containing the active component suspended or dissolved in one
or more carriers. Carriers for topical administration of compounds of this invention include, but
are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol,
polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively,
provided pharmaceutically acceptable compositions can be formulated in a suitable lotion or
cream containing the active components suspended or dissolved in one or more pharmaceutically
acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan
monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl
alcohol and water.
[0072] For ophthalmic use, provided pharmaceutically acceptable compositions may be
formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as
solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as
benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutically acceptable
compositions may be formulated in an ointment such as petrolatum.
[0073] Pharmaceutically acceptable compositions of this invention may also be administered
by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-
known in the art of pharmaceutical formulation and may be prepared as solutions in saline,
employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance
bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
[0074] Most preferably, pharmaceutically acceptable compositions of this invention are
formulated for oral administration. Such formulations may be administered with or without
food. In some embodiments, pharmaceutically acceptable compositions of this invention are
administered without food. In other embodiments, pharmaceutically acceptable compositions of
this invention are administered with food.
[0075] Pharmaceutically acceptable compositions of this invention can be administered to
humans and other animals orally, rectally, parenterally, intracisternally, intravaginally,
intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal
spray, or the like, depending on the severity of the infection being treated. In certain
embodiments, the compounds of the invention may be administered orally or parenterally at
dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to
about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired
therapeutic effect.
[0076] Liquid dosage forms for oral administration include, but are not limited to,
pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and
elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents
commonly used in the art such as, for example, water or other solvents, solubilizing agents and
emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl
alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in
particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol,
tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures
thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting
agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
[0077] Injectable preparations, for example, sterile injectable aqueous or oleaginous
suspensions may be formulated according to the known art using suitable dispersing or wetting
agents and suspending agents. The sterile injectable preparation may also be a sterile injectable
solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for
example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may
be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In
addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For
this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In
addition, fatty acids such as oleic acid are used in the preparation of injectables.
[0078] Injectable formulations can be sterilized, for example, by filtration through a
bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid
compositions which can be dissolved or dispersed in sterile water or other sterile injectable
medium prior to use.
[0079] In order to prolong the effect of a compound of the present invention, it is often
desirable to slow the absorption of the compound from subcutaneous or intramuscular injection.
This may be accomplished by the use of a liquid suspension of crystalline or amorphous material
with poor water solubility. The rate of absorption of the compound then depends upon its rate of
dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively,
delayed absorption of a parenterally administered compound form is accomplished by dissolving
or suspending the compound in an oil vehicle. Injectable depot forms are made by forming
microencapsule matrices of the compound in biodegradable polymers such as polylactide-
polyglycolide. Depending upon the ratio of compound to polymer and the nature of the
particular polymer employed, the rate of compound release can be controlled. Examples of other
biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable
formulations are also prepared by entrapping the compound in liposomes or microemulsions that
are compatible with body tissues.
[0080] Compositions for rectal or vaginal administration are preferably suppositories which
can be prepared by mixing the compounds of this invention with suitable non-irritating
excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are
solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or
vaginal cavity and release the active compound.
[0081] Solid dosage forms for oral administration include capsules, tablets, pills, powders,
and granules. In such solid dosage forms, the active compound is mixed with at least one inert,
pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate
and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic
acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin,
polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating
agents such as agar--agar, calcium carbonate, potato or tapioca starch, alginic acid, certain
silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption
accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example,
cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i)
lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium
lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form
may also comprise buffering agents.
[0082] Solid compositions of a similar type may also be employed as fillers in soft and hard-
filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular
weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules,
pills, and granules can be prepared with coatings and shells such as enteric coatings and other
coatings well known in the pharmaceutical formulating art. They may optionally contain
opacifying agents and can also be of a composition that they release the active ingredient(s) only,
or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
Examples of embedding compositions that can be used include polymeric substances and waxes.
Solid compositions of a similar type may also be employed as fillers in soft and hard-filled
gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight
polethylene glycols and the like.
[0083] The active compounds can also be in micro-encapsulated form with one or more
excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and
granules can be prepared with coatings and shells such as enteric coatings, release controlling
coatings and other coatings well known in the pharmaceutical formulating art. In such solid
dosage forms the active compound may be admixed with at least one inert diluent such as
sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice,
additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids
such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and
pills, the dosage forms may also comprise buffering agents. They may optionally contain
opacifying agents and can also be of a composition that they release the active ingredient(s) only,
or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
Examples of embedding compositions that can be used include polymeric substances and waxes.
[0084] Dosage forms for topical or transdermal administration of a compound of this
invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants
or patches. The active component is admixed under sterile conditions with a pharmaceutically
acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic
formulation, ear drops, and eye drops are also contemplated as being within the scope of this
invention. Additionally, the present invention contemplates the use of transdermal patches,
which have the added advantage of providing controlled delivery of a compound to the body.
Such dosage forms can be made by dissolving or dispensing the compound in the proper
medium. Absorption enhancers can also be used to increase the flux of the compound across the
skin. The rate can be controlled by either providing a rate controlling membrane or by
dispersing the compound in a polymer matrix or gel.
[0085] The amount of compounds of the present invention that may be combined with the
carrier materials to produce a composition in a single dosage form will vary depending upon the
host treated, the particular mode of administration. Preferably, provided compositions should be
formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of the inhibitor can be
administered to a patient receiving these compositions.
[0086] A compound of the current invention can be administered alone or in combination
with one or more other therapeutic compounds, possible combination therapy taking the form of
fixed combinations or the administration of a compound of the invention and one or more other
therapeutic compounds being staggered or given independently of one another, or the combined
administration of fixed combinations and one or more other therapeutic compounds. A
compound of the current invention can besides or in addition be administered especially for
tumor therapy in combination with chemotherapy, radiotherapy, immunotherapy, phototherapy,
surgical intervention, or a combination of these. Long-term therapy is equally possible as is
adjuvant therapy in the context of other treatment strategies, as described above. Other possible
treatments are therapy to maintain the patient's status after tumor regression, or even
chemopreventive therapy, for example in patients at risk.
[0087] Those additional agents may be administered separately from an inventive
compound-containing composition, as part of a multiple dosage regimen. Alternatively, those
agents may be part of a single dosage form, mixed together with a compound of this invention in
a single composition. If administered as part of a multiple dosage regime, the two active agents
may be submitted simultaneously, sequentially or within a period of time from one another
normally within five hours from one another.
[0088] As used herein, the term “combination,” “combined,” and related terms refers to the
simultaneous or sequential administration of therapeutic agents in accordance with this
invention. For example, a compound of the present invention may be administered with another
therapeutic agent simultaneously or sequentially in separate unit dosage forms or together in a
single unit dosage form. Accordingly, the present invention provides a single unit dosage form
comprising a compound of the current invention, an additional therapeutic agent, and a
pharmaceutically acceptable carrier, adjuvant, or vehicle.
[0089] The amount of both an inventive compound and additional therapeutic agent (in those
compositions which comprise an additional therapeutic agent as described above) that may be
combined with the carrier materials to produce a single dosage form will vary depending upon
the host treated and the particular mode of administration. Preferably, compositions of this
invention should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of
an inventive compound can be administered.
[0090] In those compositions which comprise an additional therapeutic agent, that additional
therapeutic agent and the compound of this invention may act synergistically. Therefore, the
amount of additional therapeutic agent in such compositions will be less than that required in a
monotherapy utilizing only that therapeutic agent.
[0091] The amount of additional therapeutic agent present in the compositions of this
invention will be no more than the amount that would normally be administered in a composition
comprising that therapeutic agent as the only active agent. Preferably the amount of additional
therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of
the amount normally present in a composition comprising that agent as the only therapeutically
active agent.
[0092] It should also be understood that a specific dosage and treatment regimen for any
particular patient will depend upon a variety of factors, including the activity of the specific
compound employed, the age, body weight, general health, sex, diet, time of administration, rate
of excretion, drug combination, and the judgment of the treating physician and the severity of the
particular disease being treated. The amount of a compound of the present invention in the
composition will also depend upon the particular compound in the composition.
Uses of Compounds and Pharmaceutically Acceptable Compositions
[0093] Compounds and compositions described herein are generally useful for the inhibition
of PAD4.
[0094] The activity of a compound utilized in this invention as an inhibitor of PAD4, may be
assayed in vitro, in vivo or in a cell line. In vitro assays include assays that determine the
inhibition of PAD4. Detailed conditions for assaying a compound utilized in this invention as an
inhibitor of PAD4 are set forth in the Examples below. In some embodiments, a provided
compound inhibits PAD4 selectively as compared to PAD2.
[0095] As used herein, the terms “treatment,” “treat,” and “treating” refer to reversing,
alleviating, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or
more symptoms thereof, as described herein. In some embodiments, treatment may be
administered after one or more symptoms have developed. In other embodiments, treatment may
be administered in the absence of symptoms. For example, treatment may be administered to a
susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms
and/or in light of genetic or other susceptibility factors). Treatment may also be continued after
symptoms have resolved, for example to prevent or delay their recurrence.
[0096] Provided compounds are inhibitors of PAD4and are therefore useful for treating one
or more disorders associated with activity of PAD4. Thus, in certain embodiments, the present
invention provides a method for treating a PAD4-mediated disorder comprising the step of
administering to a patient in need thereof a compound of the present invention, or
pharmaceutically acceptable composition thereof.
[0097] In one embodiment, a PAD4-mediated disorder is a disease, condition, or disorder
mediated by inappropriate PAD4 activity. In some embodiments, a PAD4-mediated disorder is
selected from the group consisting of rheumatoid arthritis, vasculitis, systemic lupus
erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis,
and psoriasis. In a further embodiment, the disorder mediated by inappropriate PAD4 activity is
rheumatoid arthritis. In a further embodiment, the disorder mediated by inappropriate PAD4
activity is systemic lupus. In a further embodiment, the disorder mediated by inappropriate
PAD4 activity is vasculitis. In a further embodiment, the disorder mediated by inappropriate
PAD4 activity is cutaneous lupus erythematosis. In a further embodiment, the disorder mediated
by inappropriate PAD4 activity is psoriasis.
[0098] In one embodiment there is provided a method of treatment of rheumatoid arthritis,
vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma,
cutaneous lupus erythematosis, or psoriasis, which method comprises administering to a human
subject in need thereof, a therapeutically effective amount of a provided compound or a
pharmaceutically acceptable salt thereof.
[0099] In one embodiment there is provided a method of treatment of rheumatoid arthritis,
which method comprises administering to a human subject in need thereof, a therapeutically
effective amount of a provided compound, or a pharmaceutically acceptable salt thereof. In one
embodiment there is provided a method of treatment of systemic lupus, which method comprises
administering to a human subject in need thereof, a therapeutically effective amount of a
provided compound, or a pharmaceutically acceptable salt thereof. In one embodiment there is
provided a method of treatment of vasculitis, which method comprises administering to a human
subject in need thereof, a therapeutically effective amount of a provided compound, or a
pharmaceutically acceptable salt thereof. In one embodiment there is provided a method of
treatment of cutaneous lupus erythematosis, which method comprises administering to a human
subject in need thereof, a therapeutically effective amount of a provided compound, or a
pharmaceutically acceptable salt thereof. In one embodiment there is provided a method of
treatment of psoriasis, which method comprises administering to a human subject in need
thereof, a therapeutically effective amount of a provided compound, or a pharmaceutically
acceptable salt thereof.
[00100] In some embodiments, a PAD4-mediated disorder is selected from the group
consisting of acid-induced lung injury, acne (PAPA), acute lymphocytic leukemia, acute,
respiratory distress syndrome, Addison’s disease, adrenal hyperplasia, adrenocortical
insufficiency, ageing, AIDS, alcoholic hepatitis, alcoholic hepatitis, alcoholic liver disease,
allergen induced asthma, allergic bronchopulmonary, aspergillosis, allergic conjunctivitis,
alopecia, Alzheimer’s disease, amyloidosis, amyotropic lateral sclerosis, and weight loss, angina
pectoris, angioedema, anhidrotic ecodermal dysplasia-ID, ankylosing spondylitis, anterior
segment, inflammation, antiphospholipid syndrome, aphthous stomatitis, appendicitis, arthritis,
asthma, atherosclerosis, atopic dermatitis, autoimmune diseases, autoimmune hepatitis, bee
sting-induced inflammation, behcet’s disease, Behcet’s syndrome, Bells Palsey, berylliosis, Blau
syndrome, bone pain, bronchiolitis, burns, bursitis, cancer, cardiac hypertrophy, carpal tunnel
syndrome, catabolic disorders, cataracts, cerebral aneurysm, chemical irritant-induced
inflammation, chorioretinitis, chronic heart failure, chronic lung disease of prematurity, chronic
lymphocytic leukemia, chronic obstructive pulmonary disease, colitis, complex regional pain
syndrome, connective tissue disease, corneal ulcer, crohn’s disease, cryopyrin-associated
periodic syndromes, cyrptococcosis, cystic fibrosis, deficiency of the interleukin-1–receptor
antagonist (DIRA), dermatitis, dermatitis endotoxemia, dermatomyositis, diffuse intrinsic
pontine glioma, endometriosis, endotoxemia, epicondylitis, erythroblastopenia, familial
amyloidotic polyneuropathy, familial cold urticarial, familial mediterranean fever, fetal growth
retardation, glaucoma, glomerular disease, glomerular nephritis, gout, gouty arthritis, graft-
versus-host disease, gut diseases, head injury, headache, hearing loss, heart disease, hemolytic
anemia, Henoch-Scholein purpura, hepatitis, hereditary periodic fever syndrome, herpes zoster
and simplex, HIV-1, Hodgkin’s disease, Huntington’s disease, hyaline membrane disease,
hyperammonemia, hypercalcemia, hypercholesterolemia, hyperimmunoglobulinemia D with
recurrent fever (HIDS), hypoplastic and other anemias, hypoplastic anemia, idiopathic
thrombocytopenic purpura, incontinentia pigmenti, infectious mononucleosis, inflammatory
bowel disease, inflammatory lung disease, inflammatory neuropathy, inflammatory pain, insect
bite-induced inflammation, iritis, irritant-induced inflammation, ischemia/reperfusion, juvenile
rheumatoid arthritis, keratitis, kidney disease, kidney injury caused by parasitic infections,
kidney injury caused by parasitic infections, kidney transplant rejection prophylaxis,
leptospiriosis, leukemia, Loeffler’s syndrome, lung injury, lung injury, lupus, lupus, lupus
nephritis, lymphoma, meningitis, mesothelioma, mixed connective tissue disease, Muckle-Wells
syndrome (urticaria deafness amyloidosis), multiple sclerosis, muscle wasting, muscular
dystrophy, myasthenia gravis, myocarditis, mycosis fungiodes, mycosis fungoides,
myelodysplastic syndrome, myositis, nasal sinusitis, necrotizing enterocolitis, neonatal onset
multisystem inflammatory disease (NOMID), nephrotic syndrome, neuritis, neuropathological
diseases, non-allergen induced asthma, obesity, ocular allergy, optic neuritis, organ transplant,
osterarthritis, otitis media, paget’s disease, pain, pancreatitis, Parkinson’s disease, pemphigus,
pericarditis, periodic fever, periodontitis, peritoneal endometriosis, pertussis, pharyngitis and
adenitis (PFAPA syndrome), plant irritant-induced inflammation, pneumonia, pneumonitis,
pneumosysts infection, poison ivy/ urushiol oil-induced inflammation, polyarteritis nodosa,
polychondritis, polycystic kidney disease, polymyositis, psoriasis, psoriasis, psoriasis, psoriasis,
psychosocial stress diseases, pulmonary disease, pulmonary hypertension, pulmonayr fibrosis,
pyoderma gangrenosum, pyogenic sterile arthritis, renal disease, retinal disease, rheumatic
carditis, rheumatic disease, rheumatoid arthritis, sarcoidosis, seborrhea, sepsis, severe pain,
sickle cell, sickle cell anemia, silica-induced disease, Sjogren’s syndrome, skin diseases, sleep
apnea, solid tumors, spinal cord injury, Stevens-Johnson syndrome, stroke, subarachnoid
hemorrhage, sunburn, temporal arteritis, tenosynovitis, thrombocytopenia, thyroiditis, tissue
transplant, TNF receptor associated periodic syndrome (TRAPS), toxoplasmosis, transplant,
traumatic brain injury, tuberculosis, type 1 diabetes, type 2 diabetes, ulcerative colitis, urticarial,
uveitis, and Wegener’s granulomatosis.
[00101] In one embodiment, the invention provides a provided compound, or a
pharmaceutically acceptable salt thereof, for use in therapy. In another embodiment, the
invention provides a provided compound, or a pharmaceutically acceptable salt thereof, for use
in the treatment of a disorder mediated by inappropriate PAD4 activity. In another embodiment,
the invention provides a provided compound, or a pharmaceutically acceptable salt thereof, for
use in the treatment of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative
colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, or psoriasis. In another
embodiment, the invention provides a provided compound, or a pharmaceutically acceptable salt
thereof, for use in the treatment of rheumatoid arthritis. In another embodiment, the invention
provides a provided compound, or a pharmaceutically acceptable salt thereof, for use in the
treatment of systemic lupus. In another embodiment, the invention provides a provided
compound, or a pharmaceutically acceptable salt thereof, for use in the treatment of vasculitis.
In another embodiment, the invention provides a provided compound, or a pharmaceutically
acceptable salt thereof, for use in the treatment of cutaneous lupus erythematosis. In another
embodiment, the invention provides a provided compound, or a pharmaceutically acceptable salt
thereof, for use in the treatment of psoriasis. In another embodiment, the invention provides the
use of a provided compound, or a pharmaceutically acceptable salt thereof, in the manufacture of
a medicament for use in the treatment of a disorder mediated by inappropriate PAD4 activity. In
another embodiment, the invention provides the use of a provided compound, or a
pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the
treatment of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis,
cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, or psoriasis. In another
embodiment, the invention provides the use of a provided compound, or a pharmaceutically
acceptable salt thereof, in the manufacture of a medicament for use in the treatment of
rheumatoid arthritis. In another embodiment, the invention provides the use of a provided
compound, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for
use in the treatment of systemic lupus. In another embodiment, the invention provides the use of
a provided compound, or a pharmaceutically acceptable salt thereof, in the manufacture of a
medicament for use in the treatment of vasculitis. In another embodiment, the invention
provides the use of a provided compound, or a pharmaceutically acceptable salt thereof, in the
manufacture of a medicament for use in the treatment of cutaneous lupus erythematosis. In
another embodiment, the invention provides the use of a provided compound, or a
pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the
treatment of psoriasis. In a further embodiment, the invention provides a pharmaceutical
composition for the treatment or prophylaxis of a disorder mediated by inappropriate PAD4
activity comprising a provided compound, or a pharmaceutically acceptable salt thereof. In a
further embodiment, the invention provides a pharmaceutical composition for the treatment or
prophylaxis of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis,
cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, or psoriasis, comprising a
provided compound, or a pharmaceutically acceptable salt thereof. In a further embodiment, the
invention provides a pharmaceutical composition for the treatment or prophylaxis of rheumatoid
arthritis comprising a provided compound, or a pharmaceutically acceptable salt thereof. In a
further embodiment, the invention provides a pharmaceutical composition for the treatment or
prophylaxis of systemic lupus comprising a provided compound, or a pharmaceutically
acceptable salt thereof. In a further embodiment, the invention provides a pharmaceutical
composition for the treatment or prophylaxis of vasculitis comprising a provided compound, or a
pharmaceutically acceptable salt thereof. In a further embodiment, the invention provides a
pharmaceutical composition for the treatment or prophylaxis of cutaneous lupus erythematosis
comprising a provided compound, or a pharmaceutically acceptable salt thereof. In a further
embodiment, the invention provides a pharmaceutical composition for the treatment or
prophylaxis of psoriasis comprising a provided compound, or a pharmaceutically acceptable salt
thereof
[00102] All features of each of the aspects of the invention apply to all other aspects mutatis
mutandis.
[00103] In order that the invention described herein may be more fully understood, the
following examples are set forth. It should be understood that these examples are for illustrative
purposes only and are not to be construed as limiting this invention in any manner.
EXEMPLIFICATION
[00104] As depicted in the Examples below, in certain exemplary embodiments, compounds
are prepared according to the following general procedures. It will be appreciated that, although
the general methods depict the synthesis of certain compounds of the present invention, the
following general methods, and other methods known to one of ordinary skill in the art, can be
applied to all compounds and subclasses and species of each of these compounds, as described
herein.
[00105] Preparative HPLC methods
[00106] Basic HPLC preparative method
Column: XBridgeTM Prep. C18 10 um OBDTM, 30 x 100 mm
Mobile Phase: 5 - 95 % Acetonitrile (0. 2 % ammonium hydroxide) in Water (0. 2 % ammonium
hydroxide) over 14 minutes
Flow Rate: 40 mL/min
UV Detection: 215 and 254 nm
[00107] Acidic HPLC preparative method
Column: SunfireTM Prep. C18 10 um OBDTM, 30 x 100 mm
Mobile Phase: 5 - 95 % Acetonitrile (0. 1 % formic acid) in Water (0. 1 % formic acid) over 14
minutes
Flow Rate: 40 mL/min
UV Detection: 215 and 254 nm
[00108] Analytical LCMS methods:
[00109] Method A
MET/u-HPLC (low pH MSQ1 7 min method)
Column: Phenomenex Kinetex-XB C18, 2.1 mm x 100 mm, 1.7 µm
Flow rate: 0.6 ml/min
Mobile Phase: A, Formic acid (aqueous) 0.1% and B, Formic acid (MeCN) 0.1%
Injection Vol: 3 µl
Temp.: 40 ºC
Detection: 215 nm (nominal)






MET/CR/1600 (high pH MS10 7 min method)
Column: Phenomenex Gemini C18, 2.0mm x 100mm, 3µm
Flow rate: 0.5ml/min
Mobile phase: A, 2mM ammonium bicarbonate in HPLC grade water pH10
B HPLC grade MeCN
Injection volume: 3 µl
Temperature: 50 ºC
Detection: 215nm







METCR 1416 (low pH Shimadzu 7min method)
Column: Waters Atlantis dC18, 2.1mm x 100mm, 3µm column
Flow rate: 0.6 ml/min
Mobile Phase: A, Formic acid (aqueous) 0.1% and B, Formic acid (acetonitrile) 0.1%
Injection Vol: 3 µl
Temp.: 40 ºC
Detection: 215 nm (nominal)






METCR 1410 (low pH Shimadzu 2min method)
Column: Kinetex Core-Shell C18, 2.1mm x 50mm, 5µm column
Flow rate: 1.2 ml/min
Mobile Phase: A, Formic acid (aqueous) 0.1% and B, Formic acid (acetonitrile) 0.1%
Injection Vol: 3 µl
Temp.: 40 ºC
Detection: 215 nm (nominal)






MET/u-HPLC (high pH MS16 7 min method)
Column: Waters UPLC CSH C18, 2.1mm x 100mm 5µm column
Flow rate: 0.6 ml/min
Mobile Phase: A, 2mM Ammonium bicarbonate modified to pH 10 with Ammonium hydroxide
(aqueous) and B, acetonitrile
Injection Vol: 3 µl
Temp.: 40 ºC
Detection: 215 nm (nominal)






MET/CR/0990 (high pH 3min method)
Column: Phenomenex Gemini C18, 2.0mm x 100mm, 3µm
Flow rate: 1ml/min
Mobile phase: A, 2mM ammonium bicarbonate in HPLC grade water pH10
B HPLC grade MeCN
Injection volume: 3 µl
Temperature: 60 ºC
Detection: 215nm





[00115] Analytical and preparative chiral HPLC methods:
[00116] Method E:
Chiral HPLC preparative method
Column: Chiralpak IC 250mm x 4.6mm, 5µm column
Flow rate: 15 ml/min
Mobile Phase: 35% Ethanol: 65%CO2
Sample Diluent: Ethanol
Temp.: 40°C
Detection: 215 nm (nominal)
[00117] Method F:
Chiral purity analysis method
Column: Chiralpak IC 250mm x 4.6mm, 5µm column
Flow Rate: 4 ml/min
Injection Vol: 10 µL
Temp.: 40°C
Detection: 215 nm
Isocratic Conditions 40% Ethanol: 60%CO2
[00118] Certain compounds of the present invention were prepared according to Schemes 1
and 2, below.
Scheme 1
[00119] Synthesis of (3R)-1-{2-[1-(cyclopropylmethyl)-5-phenyl-1H-pyrrol-2-yl]-1-
methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-amine hydrochloride I-9
EOAI3428252 (EV-AR0067-002)
[00120] Methyl 5-phenyl-1H-pyrrole-2-carboxylate (EV-AR0054-002) – Step 1
[00121] To a solution of 5-phenyl-1H-pyrrole-2-carboxylic acid (500 mg, 2.67 mmol) in
toluene (10ml) and methanol (3 ml) was added 2M (diazomethyl)(trimethyl)silane in hexane (2
ml) and the mixture was stirred under nitrogen at room temperature for 30 minutes. To the
reaction mixture was added acetic acid (1 ml) and the mixture was concentrated in vacuo to
afford 530 mg (99%) of methyl 5-phenyl-1H-pyrrole-2-carboxylate (EV-AR0054-002) as a pale
yellow powder. LCMS (method D): retention time 1.14min, M/z = 202.0 (M + 1).
[00122] 1-(Cyclopropylmethyl)-5-phenyl-1H-pyrrole-2-carboxylic acid (EV-AR0056-003)
– Step 2
[00123] To a solution of methyl 5-phenyl-1H-pyrrole-2-carboxylate (EV-AR0054-002, 530
mg, 2.63 mmol) in anhydrous DMF (10 ml) was added sodium hydride (60%, 120 mg, 3.00
mmol) portion wise and the resulting mixture was stirred for 15 minutes. After this time
(bromomethyl)cyclopropane (285 µl, 2.94 mmol) was added and the mixture was stirred under
nitrogen at room temperature for 72h. The mixture was treated with further
(bromomethyl)cyclopropane (450 µl, 4.65 mmol) and sodium hydride (60%, 60 mg, 1.50 mmol)
and stirred at 40oC for 30 minutes. The reaction mixture was concentrated in vacuo and the
residue was dissolved in ethanol (8ml) and water (2 ml). 5M aqueous sodium hydroxide (2ml)
was added and the resulting mixture was stirred in a pressure tube at 80oC for 2h. The reaction
mixture was concentrated in vacuo and taken up in water (5 ml), acidified with 5N aqueous
hydrochloric acid (~5 ml) until no further precipitation was observed. The resulting suspension
was stirred on an ice bath for 15 minutes and filtered through filter paper under vacuum. The
resulting solid was dried to afford 495 mg (78%) of 1-(cyclopropylmethyl)-5-phenyl-1H-pyrrole-
2-carboxylic acid (EV-AR0056-003) as a beige powder. LCMS (method D): retention time
1.17min, M/z = 242.0 (M + 1).
[00124] Methyl 4-(methylamino)-3-nitrobenzoate (EV-AR0020-002) – Step 3
[00125] To a stirred solution of methyl 4-fluoro-3-nitrobenzoate (10.0 g, 50.2 mmol) in DMF
(100 ml) was added methanamine hydrochloride (1:1) (4.00 g, 59.2 mmol). Potassium carbonate
(99%, 9.00 g, 64.5 mmol) was added and the mixture was stirred under nitrogen at room
temperature for 18h. The reaction crude was concentrated in vacuo and partitioned between ethyl
acetate (400 ml) and 1M aqueous hydrochloric acid (2x25 ml). The organic layer was washed
with brine (25 ml), dried over sodium sulfate, filtered and concentrated in vacuo to afford 6.00 g
(57%) of methyl 4-(methylamino)-3-nitrobenzoate (EV-AR0020-002) as a yellow powder.
LCMS (method D): retention time 1.23min, M/z = 210.9 (M + 1).
[00126] Methyl 3-amino-4-(methylamino)benzoate (EV-AR0021-002) - Step 4
[00127] To a solution of methyl 4-(methylamino)-3-nitrobenzoate (EV-AR0020-002, 6.00 g,
28.6 mmol) in ethanol (100 ml) was added 10% w/w Pd/C (0.15 g, 1.41 mmol). The reaction
mixture was stirred under an atmosphere of hydrogen at room temperature for 18h. The reaction
crude was filtered through Kieselguhr and washed through with methanol (200 ml). The filtrate
was concentrated in vacuo to afford 5.00 g (97%) of methyl 3-amino-4-(methylamino)benzoate
(EV-AR0021-002) as a purple solid. LCMS (method D): retention time 0.84min, M/z = 181.0
(M + 1).
[00128] Methyl 2-[1-(cyclopropylmethyl)-5-phenyl-1H-pyrrol-2-yl]-1-methyl-1H-1,3-
benzodiazole-5-carboxylate (EV-AR0061-003) – Step 5
[00129] To a solution of 1-(cyclopropylmethyl)-5-phenyl-1H-pyrrole-2-carboxylic acid (EV-
AR0056-003, 295 mg, 1.22 mmol) in DMF (5 ml) was added DIPEA (225 µl, 1.36 mmol)
followed by HATU (520 mg, 1.37 mmol) and the resulting mixture was stirred at room
temperature for 30 minutes. Methyl 3-amino-4-(methylamino)benzoate (EV-AR0021-002, 250
mg, 1.39 mmol) was added and the mixture was stirred under nitrogen at room temperature for
3h, at 60oC for 3h and at room temperature for 16h. The mixture was then concentrated in vacuo,
the residue was suspended in acetic acid (3ml) and the resulting mixture was stirred under
nitrogen at 80oC for 7h. The solvent was removed in vacuo and the remaining material purified
by flash column chromatography (10-25% ethyl acetate/heptane) to obtain a solid which was
triturated from diethyl ether (5 ml) to afford 140 mg (29%) of methyl 2-[1-(cyclopropylmethyl)-
5-phenyl-1H-pyrrol-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carboxylate (EV-AR0061-003) as a
white powder. LCMS (method D): retention time 1.28min, M/z = 386.1 (M + 1).
[00130] 2-[1-(cyclopropylmethyl)-5-phenyl-1H-pyrrol-2-yl]-1-methyl-1H-1,3-
benzodiazole-5-carboxylic acid (EV-AR0064-002) – Step 6
[00131] To a solution of methyl 2-[1-(cyclopropylmethyl)-5-phenyl-1H-pyrrol-2-yl]-1-
methyl-1H-1,3-benzodiazole-5-carboxylate (EV-AR0061-003, 140 mg, 0.36 mmol) in THF (3
ml) was added a solution of lithium hydroxide (26 mg, 1.09 mmol) in water (3 ml) and the
resulting mixture was stirred under nitrogen at 50oC for 16h. The reaction crude was
concentrated in vacuo and taken up in water (5 ml), acidified with 5N aqueous hydrochloric acid
(~0.5 ml) until no further precipitation was observed. The resulting suspension was allowed to
stir for 30 minutes and filtered through filter paper. The resulting solid was dried to afford 130
mg (96%) of 2-[1-(cyclopropylmethyl)-5-phenyl-1H-pyrrol-2-yl]-1-methyl-1H-1,3-
benzodiazole-5-carboxylic acid (EV-AR0064-002) as a white powder. LCMS (method D):
retention time 1.13min, M/z = 372.0 (M + 1).
[00132] Tert-butyl N-[(3R)-1-{2-[1-(cyclopropylmethyl)-5-phenyl-1H-pyrrol-2-yl]-1-
methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-yl]carbamate (EV-AR0066-002) – Step
7
[00133] To a solution of 2-[1-(cyclopropylmethyl)-5-phenyl-1H-pyrrol-2-yl]-1-methyl-1H-
1,3-benzodiazole-5-carboxylic acid (EV-AR0064-002, 50 mg, 0.13 mmol) in 2:1 DMSO
acetonitrile (3 ml) was added DIPEA (26 µl, 0.16 mmol) followed by HATU (60 mg, 0.16
mmol) and the resulting mixture was stirred at room temperature for 15 minutes. To this solution
was added tert-butyl (3R)-piperidin-3-ylcarbamate (30 mg, 0.15 mmol) and the mixture was
stirred under nitrogen at room temperature for 16h. To the mixture was added 3:2 acetonitrile
water (0.5 ml), 2:1 DMSO acetonitrile (2 ml) and water (5 ml) and the resulting suspension was
filtered through filter paper under vacuum. The solid was washed with water (10 ml) and dried to
afford 53 mg (71%) of tert-butyl N-[(3R)-1-{2-[1-(cyclopropylmethyl)-5-phenyl-1H-pyrrol-2-
yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-yl]carbamate (EV-AR0066-002) as a
white powder. LCMS (method D): retention time 1.20min, M/z = 554.2 (M + 1).
[00134] (3R)-1-{2-[1-(Cyclopropylmethyl)-5-phenyl-1H-pyrrol-2-yl]-1-methyl-1H-1,3-
benzodiazole-5-carbonyl}piperidin-3-amine hydrochloride (I-9)(EV-AR0067-002) – Step 8
[00135] To a suspension of tert-butyl N-[(3R)-1-{2-[1-(cyclopropylmethyl)-5-phenyl-1H-
pyrrol-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-yl]carbamate (EV-AR0066-
002, 53 mg, 0.10 mmol) in methanol (2 ml) was added 4M hydrochloric acid in dioxane (1 ml)
and the resulting solution was stirred under air at room temperature for 2h. The reaction crude
was concentrated in vacuo and the residue was freeze-dried from water (4 ml) to obtain 46 mg
(98%) of (3R)-1-{2-[1-(cyclopropylmethyl)-5-phenyl-1H-pyrrol-2-yl]-1-methyl-1H-1,3-
benzodiazole-5-carbonyl}piperidin-3-amine hydrochloride (EV-AR0067-002) as a white
powder. LCMS (method A): retention time 2.17min, M/z = 454.2 (M + 1).
[00136] Special cases for Scheme 1
[00137] I-12
[00138] (3R)-1-{2-[1-(Cyclopropylmethyl)-5-(pyridin-2-yl)-1H-pyrrol-2-yl]-1-methyl-1H-
1,3-benzodiazole-5-carbonyl}piperidin-3-amine I-12 EV-AS5724-003 (EOAI3435373) was
synthesised according to the procedures described in Scheme 1 via methyl 1-
(cyclopropylmethyl)-5-(pyridin-2-yl)-1H-pyrrole-2-carboxylate (EV-AS5714-004) synthesised
according to Scheme 1.1
Scheme 1.1
[00139] Methyl 5-bromo-1-(cyclopropylmethyl)-1H-pyrrole-2-carboxylate (EV-AS5711-
002) – Step 1
[00140] To a solution of methyl 5-bromo-1H-pyrrole-2-carboxylate (CAS 934-07-6, 500 mg,
2.45 mmol) in anhydrous DMF (5 ml) was added sodium hydride (60%, 150 mg, 3.75 mmol). To
this solution was added (bromomethyl)cyclopropane (350 µl, 3.61 mmol) and the mixture stirred
under nitrogen at 30 °C in a sealed tube for 8h. The reaction mixture was concentrated,
quenched with methanol and purified by flash column chromatography (0-50% ethyl
acetate/heptane) to afford 566 mg (89%) of methyl 5-bromo-1-(cyclopropylmethyl)-1H-pyrrole-
2-carboxylate (EV-AS5711-002) as a yellow oil. LCMS (method D): retention time 1.44 min,
M/z = 258/260 (M + 1).
[00141] Methyl 1-(cyclopropylmethyl)-5-(pyridin-2-yl)-1H-pyrrole-2-carboxylate (EV-
AS5714-004) – Step 2
[00142] To a solution of methyl 5-bromo-1-(cyclopropylmethyl)-1H-pyrrole-2-carboxylate
(EV-AS5711-002, 566 mg, 2.19 mmol) in toluene (3 ml) was added palladium -
triphenylphosphane (1:4) (100 mg, 0.09 mmol). To this solution was added 2-
(tributylstannanyl)pyridine (0.84 ml, 2.63 mmol) and the mixture stirred under nitrogen at 110°C
for 18h. The reaction mixture was cooled, diluted with ethyl acetate (5 ml) and quenched with
1M potassium fluoride (2.5 ml). The mixture was stirred for 15 minutes, the resulting
suspension was filtered through Kieselguhr and the filter washed with ethyl acetate (100 ml).
The organic layer was washed with 1M potassium fluoride (2x6 ml), saturated aqueous sodium
chloride (6 ml) then dried over sodium sulfate, filtered and concentrated. The residue was
purified by flash column chromatography (0-50% ethyl acetate/heptane) to afford 176 mg (31%)
of methyl 1-(cyclopropylmethyl)-5-(pyridin-2-yl)-1H-pyrrole-2-carboxylate (EV-AS5714-004)
as a yellow gum. LCMS (method D): retention time 1.22 min, M/z = 257 (M + 1).
[00143] I-17
[00144] (3R)-1-{2-[1-(Cyclopropylmethyl)-5-(pyridin-3-yl)-1H-pyrrol-2-yl]-1-methyl-1H-
1,3-benzodiazole-5-carbonyl}piperidin-3-amine I-17 EV-AS5752-002 (EOAI3435970) was
synthesised according to the procedures described in Scheme 1 via methyl 1-
(cyclopropylmethyl)-5-(pyridin-3-yl)-1H-pyrrole-2-carboxylate (EV-AS5741-002) synthesised
according to Scheme 1.2
Scheme 1.2
[00145] Methyl 1-(cyclopropylmethyl)-5-(pyridin-3-yl)-1H-pyrrole-2-carboxylate (EV-
AS5741-002) – Step 1
[00146] To a solution of methyl 5-bromo-1-(cyclopropylmethyl)-1H-pyrrole-2-carboxylate
(EV-AS5714-003, 135 mg, 0.52 mmol) in dioxane (1 ml) was added pyridin-3-ylboronic acid
(75 mg, 0.61 mmol). To this solution was added 1,1'-bis(diphenylphosphanyl)ferrocene -
dichloropalladium (1:1) (15 mg, 0.02 mmol) and the mixture stirred under nitrogen at 100°C for
1h. The reaction mixture was concentrated and the residue purified by flash column
chromatography (8-50% ethyl acetate/ heptane) to afford 100 mg (71%) of methyl 1-
(cyclopropylmethyl)-5-(pyridin-3-yl)-1H-pyrrole-2-carboxylate (EV-AS5741-002) as a yellow
oil. LCMS (method D): retention time 1.08 min, M/z = 257 (M + 1).
[00147] I-22
[00148] (3R)-1-{2-[1-(Cyclopropylmethyl)-2-phenyl-1H-imidazol-4-yl]-1-methyl-1H-1,3-
benzodiazole-5-carbonyl}piperidin-3-amine I-22 EV-AS5480-001 (EOAI3441169) was
synthesised according to the procedures described in Scheme 1 via methyl 1-
(cyclopropylmethyl)-2-phenyl-1H-imidazole-4-carboxylate (EV-AS5469-002) synthesised
according to Scheme 1.3.
Scheme 1.3
[00149] Methyl 1-(cyclopropylmethyl)-2-phenyl-1H-imidazole-4-carboxylate (EV-
AS5469-002) – Step 1
[00150] To a solution of methyl 2-phenyl-1H-imidazole-5-carboxylate (EV-AS5468-002
prepared as described in scheme 1.10, 683 mg, 3.38 mmol) in THF (20 ml) at 0°C was added
potassium hexamethyldisilazane (15% solution in toluene, 5.64 ml, 3.72 mmol) and stirred for 5
mins, before (bromomethyl)cyclopropane (360 µl, 3.72 mmol) was added and stirred at 70°C for
20h. The reaction mixture was cooled to 0°C and saturated aqueous ammonium chloride (20 ml)
was added. The reaction mixture was extracted with DCM (2x20 ml), the organic extracts were
dried over sodium sulfate and concentrated. The residue was purified by flash column
chromatography (0-50% ethyl acetate/heptane) to afford 381 mg (43%) of methyl 1-
(cyclopropylmethyl)-2-phenyl-1H-imidazole-4-carboxylate (EV-AS5469-002) as a beige
powder. LCMS (method D): retention time 1.12 min, M/z = 257 (M + 1).
[00151] I-32
[00152] (3R)-1-{2-[1-(Cyclopropylmethyl)-5-(2-phenylethyl)-1H-pyrrol-2-yl]-1-methyl-1H-
1,3-benzodiazole-5-carbonyl}piperidin-3-amine hydrochloride I-32 EV-AU3425-003
(EOAI3447741) was obtained according to Scheme 1.4 from tert-butyl N-[(3R)-1-{2-[1-
(cyclopropylmethyl)-5-[(E)-2-phenylethenyl]-1H-pyrrol-2-yl]-1-methyl-1H-1,3-benzodiazole-5-
carbonyl}piperidin-3-yl]carbamate (EV-AU3418-004) which was synthesised according to the
procedures described in Schemes 1 and 1.1.
Scheme 1.4
[00153] (3R)-1-{2-[1-(cyclopropylmethyl)-5-(2-phenylethyl)-1H-pyrrol-2-yl]-1-methyl-
1H-1,3-benzodiazole-5-carbonyl}piperidin-3-amine hydrochloride (EV-AU3425-003) –
Step 1
[00154] To a solution of tert-butyl N-[(3R)-1-{2-[1-(cyclopropylmethyl)-5-[(E)-2-
phenylethenyl]-1H-pyrrol-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-
yl]carbamate (EV-AU3418-004, 17 mg, 0.03 mmol) in ethanol (2 ml) was added 10% w/w Pd/C
(2 mg, 0.02 mmol). The mixture was stirred for 5h at room temperature under a hydrogen
atmosphere and filtered through Kieselguhr. The filter was washed with methanol (20 ml) and
the filtrate was concentrated in vacuo. The obtained material was dissolved in DCM (2 ml) and
2M hydrogen chloride in diethyl ether (0.5 ml) was added. The mixture was stirred for 2h at
room temperature. The solvents were then removed under a stream of nitrogen and the material
further dried in a vacuum oven for 16h to obtain 13 mg (85%) of (3R)-1-{2-[1-
(cyclopropylmethyl)-5-(2-phenylethyl)-1H-pyrrol-2-yl]-1-methyl-1H-1,3-benzodiazole-5-
carbonyl}piperidin-3-amine hydrochloride (EV-AU3425-003) as a white powder. LCMS
(method A): retention time 2.48min, M/z = 482 (M + 1).
[00155] I-21
[00156] (3R)-1-{2-[1-(Cyclopropylmethyl)-1H-pyrrol-2-yl]-1-methyl-1H-1,3-benzodiazole-5-
carbonyl}piperidin-3-amine hydrochloride I-21 EV-AS5766-001 (EOAI3437830) was obtained
from boc-deprotection of tert-butyl N-[(3R)-1-{2-[1-(cyclopropylmethyl)-1H-pyrrol-2-yl]-1-
methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-yl]carbamate (EV-AS5765-002) obtained
according to Scheme 1.5 starting from of tert-butyl N-[(3R)-1-{2-[5-bromo-1-
(cyclopropylmethyl)-1H-pyrrol-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-




1,3-benzodiazole-5-carbonyl}piperidin-3-yl]carbamate (EV-AS5765-001) – Step 1
[00158] To a solution of tert-butyl N-[(3R)-1-{2-[5-bromo-1-(cyclopropylmethyl)-1H-pyrrol-
2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-yl]carbamate (EV-AS5763-002, 50
mg, 0.09 mmol, synthesised according to procedures described in Scheme 1) in ethanol (2ml)
was added 10% w/w Pd/C (5 mg, 0.05 mmol). The mixture was stirred for 17h at room
temperature under a hydrogen atmosphere and filtered through Kieselguhr. The filter was
washed with methanol (40 ml) and the filtrate was concentrated in vacuo to obtain 43 mg (99%)
of tert-butyl N-[(3R)-1-{2-[1-(cyclopropylmethyl)-1H-pyrrol-2-yl]-1-methyl-1H-1,3-
benzodiazole-5-carbonyl}piperidin-3-yl]carbamate (EV-AS5765-002) as a white powder. LCMS
(method D): retention time 1.07min, M/z = 478 (M + 1).
[00159] (3R)-1-{2-[1-(cyclopropylmethyl)-1H-pyrrol-2-yl]-1-methyl-1H-1,3-benzodiazole-
5-carbonyl}piperidin-3-amine hydrochloride (EV-AS5766-002) – Step 2
[00160] To a solution of tert-butyl N-[(3R)-1-{2-[1-(cyclopropylmethyl)-1H-pyrrol-2-yl]-1-
methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-yl]carbamate (EV-AS5765-002, 40 mg,
0.08 mmol) in ethanol (1 ml) was added 1.25M hydrogen chloride in ethanol (1 ml). The mixture
was stirred for 4.5h at 40°C. The solvent was removed under a stream of nitrogen and the residue
was purified by basic HPLC preparative method. The residue was dissolved in 2M aqueous
hydrogen chloride (1 ml) and the solvent was removed in vacuo. The residue was dissolved in
water (4 ml) and dried on a freeze dryer to obtain 31 mg (89%) of (3R)-1-{2-[1-
(cyclopropylmethyl)-1H-pyrrol-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-
amine hydrochloride (EV-AS5766-002) as a yellow powder. LCMS (method A): retention time
1.46min, M/z = 378 (M + 1).
[00161] I-6 and I-7
[00162] (3R)-1-[2-(1-Cyclobutyl-3-cyclopropyl-1H-pyrazol-5-yl)-1-methyl-1H-1,3-
benzodiazole-5-carbonyl]piperidin-3-amine I-6 EV-AR0050-002 (EOAI3427617) was
synthesised according to the procedures described in Scheme 1 via synthesis of methyl 1-
cyclobutyl-3-cyclopropyl-1H-pyrazole-5-carboxylate (EV-AR0034-003) as described in Scheme
1.6. (3R)-1-[2-(1-cyclobutyl-5-cyclopropyl-1H-pyrazol-3-yl)-1-methyl-1H-1,3-benzodiazole-5-
carbonyl]piperidin-3-amine I-7 EV-AR0051-002 (EOAI3427618) was synthesised according to
the procedures described in Scheme 1 via synthesis of methyl 1-cyclobutyl-5-cyclopropyl-1H-
pyrazole-3-carboxylate (EV-AR0034-004) as described in Scheme 1.6.
Scheme 1.6
[00163] Methyl 1-cyclobutyl-3-cyclopropyl-1H-pyrazole-5-carboxylate (EV-AR0034-003)
and methyl 1-cyclobutyl-5-cyclopropyl-1H-pyrazole-3-carboxylate (EV-AR0034-004) –
Step 1
[00164] To a solution of methyl 3-cyclopropyl-1H-pyrazole-5-carboxylate (CAS 1036733-11-
5, 500 mg, 3.01 mmol) in DMF (5 ml) were added potassium carbonate (832 mg, 6.02 mmol),
potassium iodide (750 mg, 4.52 mmol) and bromocyclobutane (CAS 4399-47-7, 315 µl, 3.35
mmol). The resulting mixture was stirred for 17h at 80°C. Additional bromocyclobutane (70 µl,
0.74 mmol) was added and the mixture stirred for 24h at 80°C. The solvent was removed in
vacuo, the residue was dissolved in ethyl acetate (100 ml), washed with water (3x10 ml) then
saturated sodium chloride (10 ml). The organic extract was dried over sodium sulfate and
concentrated in vacuo. The crude material was purified by flash column chromatography (25%
ethyl acetate/heptane) to obtain 2 products.
First eluting isomer: 230 mg (31%) of methyl 1-cyclobutyl-3-cyclopropyl-1H-pyrazole-5-
carboxylate (EV-AR0034-003) as a yellow oil. LCMS (method D): retention time 1.26min, M/z
= 221 (M + 1).
Second eluting isomer: 130 mg (19%) of methyl 1-cyclobutyl-5-cyclopropyl-1H-pyrazole-3-
carboxylate (EV-AR0034-004) as a colourless oil. LCMS (method D): retention time 1.12min,
M/z = 221 (M + 1).
[00165] I-36
[00166] (3R)-1-{2-[1-(Cyclopropylmethyl)-4-methyl-2-phenyl-1H-imidazol-5-yl]-1-methyl-
1H-1,3-benzodiazole-5-carbonyl}piperidin-3-amine EV-AU7213-001 (EOAI3447871) was
synthesised according to the procedures described in Scheme 1 via 1-(cyclopropylmethyl)-4-
methyl-2-phenyl-1H-imidazole-5-carboxylic acid EV-AT8656-001 synthesised according to
Scheme 1.7.
Scheme 1.7
[00167] Ethyl 2-bromo-4-methyl-1H-imidazole-5-carboxylate (EV-AT8648-001) – Step 1
[00168] To a stirred solution of ethyl 4-methyl-1H-imidazole-5-carboxylate (CAS 51605-32-
4, 500 mg, 3.24 mmol) in acetonitrile (10 ml) and chloroform (10 ml) was added N-
bromosuccinimide (577 mg, 3.24 mmol) and the reaction stirred under a nitrogen atmosphere at
room temperature for 18h. The reaction mixture was concentrated and the residue was purified
by flash column chromatography (10-100% ethyl acetate/heptane) to afford 560 mg (73%) of
ethyl 2-bromo-4-methyl-1H-imidazole-5-carboxylate (EV-AT8648-001) as an off-white solid.
LCMS (method D): retention time 0.87 min, M/z = 233/235 (M + 1).
[00169] Ethyl 2-bromo-1-(cyclopropylmethyl)-4-methyl-1H-imidazole-5-carboxylate
(EV-AT8650-001) – Step 2
[00170] To ethyl 2-bromo-4-methyl-1H-imidazole-5-carboxylate (EV-AT8648-001, 550 mg,
2.36 mmol) in DMF (10 ml), was added potassium carbonate (652 mg, 4.72 mmol) followed by
(bromomethyl)cyclopropane (0.25 ml, 2.60 mmol) and the reaction mixture stirred at room
temperature for 16h. Saturated aqueous ammonium chloride (150 ml) was added to the reaction
mixture and the aqueous layer was extracted with ethyl acetate (2x150 ml). The combined
organics were then dried over sodium sulfate and concentrated in vacuo. The residue was
purified by flash column chromatography (0-100% ethyl acetate/heptane) to afford 543 mg
(80%) of ethyl 2-bromo-1-(cyclopropylmethyl)-4-methyl-1H-imidazole-5-carboxylate (EV-
AT8650-001) as a colourless oil. LCMS (method D): retention time 1.23 min, M/z = 287/289
(M + 1).
[00171] 1-(Cyclopropylmethyl)-4-methyl-2-phenyl-1H-imidazole-5-carboxylic acid (EV-
AT8656-001) – Step 3
[00172] A pressure tube was charged with ethyl 2-bromo-1-(cyclopropylmethyl)-4-methyl-
1H-imidazole-5-carboxylate (EV-AT8650-001, 200 mg, 0.70 mmol), phenylboronic acid (127
mg, 1.04 mmol), tetrakis(triphenylphosphine)palladium(0) (20 mg, 0.017 mmol) and potassium
carbonate (154 mg, 1.11 mmol) in dioxane (2 ml) and water (0.67 ml). The mixture was purged
with nitrogen for 10 minutes and stirred at 100°C for 3h. The reaction mixture was partitioned
between ethyl acetate (100 ml) and water (80 ml). The organic extract was dried over sodium
sulfate and concentrated. The residue was purified using flash column chromatography (0-35%
ethyl acetate/heptane) to afford 172 mg (82%) of 1-(cyclopropylmethyl)-4-methyl-2-phenyl-1H-
imidazole-5-carboxylic acid (EV-AT8656-001) as a yellow oil. LCMS (method D): retention





(EOAI3450849) was synthesised according to the procedures described in Scheme 1 via
synthesis of 5-[benzyl(phenyl)carbamoyl]-1-(cyclopropylmethyl)-1H-pyrrole-2-carboxylic acid
(EV-AU3461-003) as described in Scheme 1.8.
Scheme 1.8
[00175] Ethyl 5-[benzyl(phenyl)carbamoyl]-1H-pyrrole-2-carboxylate (EV-AU3459-003)
– Step 1
[00176] To a solution of 5-(ethoxycarbonyl)-1H-pyrrole-2-carboxylic acid (CAS 952569-58-
3, 200 mg, 1.09 mmol) in DMF (5 ml) was added DIPEA (190 µl, 1.15 mmol) followed by
HATU (436 mg, 1.15 mmol). The reaction was stirred for 30 minutes and N-benzylaniline (CAS
103-32-2, 220 mg, 1.20 mmol) was added. The mixture was stirred under nitrogen for 17h at
room temperature then for 23h at 50°C. The reaction mixture was concentrated in vacuo and the
residue diluted with DCM (30 ml) and water (25 ml). The aqueous layer was extracted with
DCM (2x30 ml) and the combined organic extracts were washed with water (2x10 ml), saturated
aqueous sodium chloride (10 ml), dried over sodium sulfate and concentrated in vacuo. The
crude material was purified by flash column chromatography (100% DCM) to obtain 174 mg
(46%) of ethyl 5-[benzyl(phenyl)carbamoyl]-1H-pyrrole-2-carboxylate EV-AU3459-003 as a
white powder. LCMS (method D): retention time 2.28min. M/z = 349 (M + 1).
[00177] 5-[benzyl(phenyl)carbamoyl]-1-(cyclopropylmethyl)-1H-pyrrole-2-carboxylic
acid (EV-AU3461-003) – Step 2
[00178] To a solution of ethyl 5-[benzyl(phenyl)carbamoyl]-1H-pyrrole-2-carboxylate (174
mg, 0.50 mmol) in anhydrous DMF (3 ml) was added sodium hydride (60%, 30.1 mg, 0.75
mmol) followed by (bromomethyl)cyclopropane (73 µl, 0.75 mmol). The resulting mixture was
stirred for 17h under nitrogen at room temperature then for 8h at 50°C then for 52h at room
temperature. The reaction mixture was concentrated in vacuo and the residue was dissolved in
methanol (5 ml). 5M aqueous sodium hydroxide (0.86 ml) was added and the reaction was
stirred for 6h at 50°C. The reaction was allowed to cool to room temperature and acidified with
5N aqueous hydrogen chloride (6 ml). The resulting suspension was concentrated in vacuo and
taken up in water (3 ml). The suspension was then filtered and the solid allowed to air dry to
obtain 55 mg (83%) of 5-[benzyl(phenyl)carbamoyl]-1-(cyclopropylmethyl)-1H-pyrrole-2-
carboxylic acid (EV-AU3461-003) as a pale yellow solid. LCMS (method D): retention time




AU3491-002 (EOAI3454072) was synthesised according to the procedures described in Scheme
1 via synthesis of ethyl 1-(cyclopropylmethyl)-5-(phenylcarbamoyl)-1H-pyrrole-2-carboxylate
(EV-AU3483-002) as described in Scheme 1.9.
Scheme 1.9
[00181] Ethyl 5-(phenylcarbamoyl)-1H-pyrrole-2-carboxylate (EV-AU3481-004) – Step 1
[00182] To a solution of 5-(ethoxycarbonyl)-1H-pyrrole-2-carboxylic acid (CAS 952569-58-
3, 100 mg, 0.55 mmol) in DMF (2 ml) was added DIPEA (110 µl, 0.67 mmol) followed by
HATU (250 mg, 0.66 mmol). After stirring for 15 minutes, aniline (CAS 62-53-3, 60 µl, 0.66
mmol) was added and the mixture was stirred under nitrogen for 1.5h at room temperature. The
reaction mixture was concentrated in vacuo, the residue was diluted with ethyl acetate (100 ml)
and washed with 1N aqueous hydrogen chloride (2x20 ml), water (3x20 ml) then saturated
aqueous sodium chloride (20 ml). The organic extract was dried over sodium sulfate and
concentrated in vacuo to afford the crude material which was purified by flash column
chromatography (0 – 1% MeOH/DCM) to obtain 114 mg (81%) of ethyl 5-(phenylcarbamoyl)-
1H-pyrrole-2-carboxylate (EV-AU3481-004) as a white powder. LCMS (method D): retention
time 1.08min, M/z = 259 (M + 1).
[00183] Ethyl 1-(cyclopropylmethyl)-5-(phenylcarbamoyl)-1H-pyrrole-2-carboxylate
(EV-AU3483-002) – Step 2
[00184] To a solution of DIAD (174 µl, 0.88 mmol) in anhydrous THF (5 ml) was added
triphenylphosphane (232 mg, 0.88 mmol) at -20°C. After stirring for 30 minutes a solution of
ethyl 5-(phenylcarbamoyl)-1H-pyrrole-2-carboxylate (EV-AU3481-004, 114 mg, 0.44 mmol) in
anhydrous THF (5 ml) was added. The solution was stirred for a further 30 minutes, then
cyclopropylmethanol (54 µl, 0.67 mmol) was added and the mixture was allowed to reach room
temperature over 17h under an atmosphere of nitrogen. The solvent was removed in vacuo and
the crude material was purified by flash column chromatography (5 - 25% ethyl acetate/heptane)
to obtain 150 mg (80%) of ethyl 1-(cyclopropylmethyl)-5-(phenylcarbamoyl)-1H-pyrrole-2-
carboxylate (EV-AU3483-002) as a white powder. LCMS (method D): retention time 1.29min,
M/z = 313 (M + 1).
[00185] I-23
[00186] (3R)-1-{2-[1-(cyclopropylmethyl)-2-phenyl-1H-imidazol-5-yl]-1-methyl-1H-1,3-
benzodiazole-5-carbonyl}piperidin-3-amine I-23 EV-AT8676-001 (EOAI3441286) was
synthesised according to the procedures described in Scheme 1 via synthesis of methyl 1-
(cyclopropylmethyl)-2-phenyl-1H-imidazole-5-carboxylate (EV-AT8667-001) as described in
Scheme 1.10.
Scheme 1.10
[00187] Methyl 2-phenyl-1H-imidazole-5-carboxylate (EV-AT8666-001) – Step 1
[00188] To a suspension of N-hydroxybenzenecarboximidamide (CAS 613-92-3, 3.91 g, 28.7
mmol) in methanol (20 ml) was added methyl prop-2-ynoate (CAS 922-67-8, 2.55 ml, 28.7
mmol). The mixture was stirred at 60°C under nitrogen for 1h, concentrated in vacuo, azeotroped
with toluene (20 ml) and the solvents were removed in vacuo. Diphenyl ether was added to the
resulting solid and the mixture was stirred at 200°C for 30 minutes. The reaction was allowed to
cool to room temperature and diethyl ether (100 ml) was added. The resulting solid was filtered
off and purified by flash column chromatography (10 - 80% ethyl acetate/heptane) to obtain 0.52
g (8.6%) of methyl 2-phenyl-1H-imidazole-5-carboxylate (EV-AT8666-001) as an off white
powder. LCMS (method D): retention time 0.80min, M/z = 203 (M + 1).
[00189] Methyl 1‐(cyclopropylmethyl)‐2‐phenyl‐1H‐imidazole‐5‐carboxylate (EV-
AT8667-001) – Step 2
[00190] To a suspension of methyl 2-phenyl-1H-imidazole-4-carboxylate (EV-AT8666-001,
624 mg, 3.09 mmol) and potassium carbonate (853 mg, 6.17 mmol) in DMF (10 ml) was added
(bromomethyl)cyclopropane (0.36 ml, 3.70 mmol). The mixture was left stirring for 16h at room
temperature then the mixture was partitioned between ethyl acetate (100 ml) and water (100 ml).
The organic extract was dried over sodium sulfate, filtered and concentrated. The residue was
purified by flash column chromatography (10 - 60% ethyl acetate/heptane) to obtain 235 mg
(29%) of methyl 1‐(cyclopropylmethyl)‐2‐phenyl‐1H‐imidazole‐5‐carboxylate (EV-AT8667-
001) as a yellow oil. LCMS (method D): retention time 1.05min, M/z = 257 (M + 1).
[00191] I-58
[00192] (3R)-1-[2-(1-Benzyl-2-methyl-1H-imidazol-4-yl)-7-methoxy-1-methyl-1H-1,3-
benzodiazole-5-carbonyl]piperidin-3-amine I-58 EV-AW5508-001 (EOAI3456187) was
synthesised according to the procedures described in Scheme 1 via the synthesis of methyl 1-
benzyl-2-methyl-1H-imidazole-4-carboxylate (EV-AV3888-001) as described in Scheme 1.11.
Scheme 1.11
[00193] (Z)-N-hydroxyethenecarbonimidoyl chloride (EV-AV3883-001) – Step 1
[00194] To a solution of (E)-N-ethylidenehydroxylamine (CAS 107-29-9, 0.50 g, 8.46 mmol)
in DMF (20 mL) was added 1-chloropyrrolidine-2,5-dione (685.06 µl, 8.46 mmol) and the
reaction was left to stir at room temperature for 2h. The mixture was diluted with water (10 ml)
and extracted with ethyl acetate (2x10 ml). The combined organic extracts were washed with
water (3x10 ml), saturated aqueous sodium chloride (10 ml), dried over sodium sulfate and
concentrated in vacuo to obtain 0.79 g (assumed quantitative) of (Z)-N-
hydroxyethenecarbonimidoyl chloride (EV-AV3883-001) as a colourless oil.
[00195] (Z)-N-benzyl-N'-hydroxyethenimidamide (EV-AV3886-001) – Step 2
[00196] To a solution of (Z)-N-hydroxyethenecarbonimidoyl chloride (EV-AV3883-001, 0.80
g, 8.56 mmol) in diethyl ether (20 ml) at 0°C was added triethylamine (1.19 ml, 8.56 mmol) and
phenylmethanamine (0.93 ml, 8.56 mmol) and the reaction was stirred at 0°C for 2h. The
mixture was then diluted with water (10 ml) and extracted with DCM (3x10 ml). The combined
organic extracts were washed with water (10 ml), saturated aqueous sodium chloride (10 ml),
dried over sodium sulfate and concentrated in vacuo to obtain 730 mg (52%) of (Z)-N-benzyl-
N'-hydroxyethenimidamide (EV-AV3886-001) as a white powder. LCMS (method D): retention
time 0.37min, M/z = 165 (M + 1).
[00197] Methyl 1-benzyl-2-methyl-1H-imidazole-4-carboxylate (EV-AV3888-001) – Step
3
[00198] To a solution of (Z)-N-benzyl-N'-hydroxyethenimidamide (EV-AV3886-001, 730
mg, 4.45 mmol) in methanol (12 ml) was added methyl prop-2-ynoate (CAS 922-67-8, 404.26
µl, 4.54 mmol). The mixture was stirred at 65°C under nitrogen for 5h. The mixture was then
concentrated in vacuo, toluene (3 ml) was added and the mixture was concentrated in vacuo to
afford an orange oil. Diphenyl ether (12 ml) was added and the mixture was left stirring at
200°C for 20 minutes. The reaction was cooled to room temperature and the mixture was
purified by flash column chromatography (10 - 100% ethyl acetate/heptanes then 0 - 20%
MeOH/ethyl acetate) to obtain 320mg (30%) of methyl 1-benzyl-2-methyl-1H-imidazole-4-
carboxylate (EV-AV3888-001) as a brown oil. LCMS (method D): retention time 0.77min, M/z
= 231 (M + 1).
[00199] I-55
[00200] 5-{5-[(3R)-3-Aminopiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-
benzodiazol-2-yl}-1-benzyl-1H-pyrrole-2-carbonitrile I-55 EV-AW5300-001 (EOAI3455897)
was synthesised according to the procedures described in Scheme 1 via the synthesis of methyl
1-benzyl-5-cyano-1H-pyrrole-2-carboxylate (EV-AU7292-001) as described in Scheme 1.12.
Scheme 1.12
[00201] Methyl 1-benzyl-5-bromo-1H-pyrrole-2-carboxylate (EV-AU7290-001) – Step 1
[00202] To a solution of DIAD (1.03 ml, 4.90 mmol) in dry THF (5 ml) under nitrogen at -
20°C was added a solution of triphenylphosphine (1.30 g, 4.90 mmol) in dry THF (10 ml). The
mixture was stirred for 30 minutes and a solution of methyl 5-bromo-1H-pyrrole-2-carboxylate
(CAS 934-07-6, 500 mg, 2.45 mmol) in dry THF (5 ml) was added. The mixture was stirred at -
20°C for a further 30 minutes and phenylmethanol (CAS 100-51-6, 0.38 ml, 3.67 mmol) in dry
THF (5 ml) was added dropwise at -20°C and the reaction mixture was allowed to warm to room
temperature and stirred for 62h. The solvent was removed in vacuo and the crude material was
purified by flash column chromatography (5 - 30% ethyl acetate/heptane) to obtain 730 mg
(99%) of methyl 1-benzyl-5-bromo-1H-pyrrole-2-carboxylate (EV-AU7290-001) as a pale
yellow oil. LCMS (method D): retention time 1.32min, M/z = 294/296 (M + 1).
[00203] Methyl 1-benzyl-5-cyano-1H-pyrrole-2-carboxylate (EV-AU7292-001) – Step 2
[00204] To a solution of methyl 1-benzyl-5-bromo-1H-pyrrole-2-carboxylate (EV-AU7290-
001, 300 mg, 1.00 mmol) in NMP (5 ml) was added copper cyanide (107 mg, 1.2 mmol). The
resulting mixture was heated at 160°C in a sealed tube for 16h. The reaction was allowed to cool
to room temperature and poured into an aqueous 10% EDTA solution in 1M sodium hydroxide
(30 ml). The resulting mixture was stirred at room temperature for 30 minutes. The aqueous
mixture was extracted with ethyl acetate (3x20 ml) and the combined organic extracts were
washed with saturated aqueous sodium chloride (10 ml), dried over sodium sulfate and
concentrated in vacuo. The crude material was purified by flash column chromatography (5 -
30% ethyl acetate/heptane) to obtain 142 mg (58%) of methyl 1-benzyl-5-cyano-1H-pyrrole-2-
carboxylate (EV-AU7292-001) as a colourless oil. LCMS (method D): retention time 1.21min,
M/z = 241 (M + 1).
[00205] I-56
[00206] 5-{5-[(3R)-3-Aminopiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-
benzodiazol-2-yl}-1-benzyl-1H-pyrrole-2-carboxamide I-56 EV-AW5302-001 (EOAI3455898)
was synthesised from a byproduct of the synthetic route to I-55 (Scheme 1.12)
[00207] I-57
[00208] (3R)-1-[7-Methoxy-1-methyl-2-(1-phenyl-1H-pyrrol-2-yl)-1H-1,3-benzodiazole-5-
carbonyl]piperidin-3-amine I-57 EV-AW1377-001 (EOAI3456183) was synthesised according
to the procedures described in Scheme 1 via synthesis of methyl 1-phenyl-1H-pyrrole-2-
carboxylate (EV-AW1367-001) as described in Scheme 1.13.
Scheme 1.13
[00209] Methyl 1-phenyl-1H-pyrrole-2-carboxylate (EV-AW1367-001) – Step 1
[00210] Methyl 1H-pyrrole-2-carboxylate (CAS 1193-62-0, 100 mg, 0.80 mmol) and
iodobenzene (CAS 591-50-4, 107 µl, 0.96 mmol) were dissolved in toluene (2 ml) and N,N'-
dimethylethane-1,2-diamine (35 µl, 0.32 mmol) and potassium phosphate (356 mg, 1.68 mmol)
were added. The reaction was purged with nitrogen for 5 minutes then copper(I) iodide (30 mg,
0.16 mmol) was added. The mixture was stirred at 110°C for 17h. The reaction was allowed to
cool to room temperature, diluted with ethyl acetate (20 ml) and washed with water (5x10 ml).
The organic layer was dried over sodium sulfate and concentrated in vacuo. The crude material
was purified by flash column chromatography (0 – 100% ethyl acetate/heptane) to obtain 127 mg
(79%) of methyl 1-phenyl-1H-pyrrole-2-carboxylate (EV-AW1367-001) as a white powder.
LCMS (method D): retention time 1.15min, M/z = 202 (M + 1).
[00211] I-13
[00212] (3R)-1-{2-[1-(Cyclopropylmethyl)-5-phenyl-1H-imidazol-2-yl]-1-methyl-1H-1,3-
benzodiazole-5-carbonyl}piperidin-3-amine I-13 EV-AS5448-002 (EOAI3435745) was
synthesised according to the procedures described in Scheme 1 via synthesis of ethyl 1-
(cyclopropylmethyl)-5-phenyl-1H-imidazole-2-carboxylate (EV-AS5437-001) as described in
Scheme 1.14.
Scheme 1.14
[00213] 1-(Cyclopropylmethyl)-5-phenyl-1H-imidazole (EV-AS5429-002) – Step 1
[00214] To a solution of 5-phenyl-1,3-oxazole (CAS 1006-68-4, 1.00 g, 6.90 mmol) and
cyclopropyl-methylamine (CAS 2516-47-4, 980 mg, 13.8 mmol) in o-dichlorobenzene (10 ml)
was added trifluoroacetic acid (1.054 ml, 13.78 mmol). The reaction was stirred at 200°C under
microwave irradiation for 1.5h. The mixture was poured into a mixture of 1M aqueous sodium
hydroxide (20 ml) and saturated aqueous sodium chloride (40 ml) and extracted with ethyl
acetate (3x20 ml). The combined organic extracts were dried over sodium sulfate and
concentrated in vacuo. The crude material was purified with an SCX-II cartridge. The cartridge
was washed sequentially with MeOH then with 2M ammonia in MeOH. The ammonia/MeOH
washings were concentrated in vacuo to obtain 250 mg of 1-(cyclopropylmethyl)-5-phenyl-1H-
imidazole (EV-AS5429-002) as a brown solid. LCMS (method D): retention time 0.71min, M/z
= 199 (M + 1).
[00215] Ethyl 1-(cyclopropylmethyl)-5-phenyl-1H-imidazole-2-carboxylate (EV-AS5437-
001) – Step 2
[00216] To a solution of 1-(cyclopropylmethyl)-5-phenyl-1H-imidazole (EV-AS5429-002, 50
mg, 0.25 mmol) in anhydrous THF (5 ml) at -60°C under nitrogen was added a 2.5M solution of
n-BuLi in hexane (119 µl, 0.30 mmol). After stirring for 30 minutes, ethylchloroformate (47 µl,
0.50 mmol) was added. The mixture was stirred at room temperature for 16h, quenched by
addition of water (10 ml) and then extracted with ethyl acetate (2x20 ml). The combined organic
extracts were dried over sodium sulfate and concentrated in vacuo to obtain 66 mg (85%) of
ethyl 1-(cyclopropylmethyl)-5-phenyl-1H-imidazole-2-carboxylate (EV-AS5437-001) as a




(EOAI3458420) was synthesised according to procedures described in Scheme 1 via synthesis of
methyl 7-cyano-2-{1-ethyl-1H-pyrrolo[2,3-b]pyridin-2-yl}-1-methyl-1H-1,3-benzodiazole-5-
carboxylate (EV-AW1386-001) as described in Scheme 1.15.
[00219] Scheme 1.15
[00220] Methyl 7-cyano-2-{1-ethyl-1H-pyrrolo[2,3-b]pyridin-2-yl}-1-methyl-1H-1,3-
benzodiazole-5-carboxylate (EV-AW1386-001) – Step 1
[00221] Copper(I) cyanide (31 mg, 0.35 mmol) was added to a stirred solution of methyl 2-[5-
bromo-1-(cyclopropylmethyl)-1H-pyrrol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-
carboxylate (EV-AW1383-001 synthesised according to Scheme 1, step 1-5, 90%, 162 mg, 0.35
mmol) in NMP (3 ml). The reaction mixture was stirred at 16°C for 17h, cooled down to room
temperature and further copper(I) cyanide (16 mg, 0.17 mmol) was added. The reaction was
stirred at for 5h. The reaction mixture was cooled to 0°C and water (30 ml) was added followed
by ethyl acetate (30 ml). The organic phase was isolated and the aqueous extracted with ethyl
acetate (2 x 10 ml). The combined organics were dried over sodium sulfate and concentrated in
vacuo. The crude material was purified by flash column chromatography (0-100% ethyl
acetate/heptane) to obtain 88 mg (49%) of ethyl 7-cyano-2-{1-ethyl-1H-pyrrolo[2,3-b]pyridin-2-
yl}-1-methyl-1H-1,3-benzodiazole-5-carboxylate (EV-AW1386-001) as a white powder. LCMS




azabicyclo[2.2.1]heptan-7-amine, I-71, EV-AW6285-001 (EOAI3461374) was synthesised
according to the procedures described in Scheme 1 via synthesis of 1-(cyclopropylmethyl)-2-(1-
methyl-1H-pyrazol-4-yl)-1H-imidazole-5-carboxylic acid (EV-AW6268-002) as described in
Scheme 1.16.
[00224 Scheme 1.16
[00225] Methyl 2-[(cyclopropylmethyl)amino]acetate EV-AW6256-001 – Step 1
[00226] To a stirred solution of cyclopropylmethanamine (CAS 2516-47-4, 4.00 g, 56.2
mmol) in acetonitrile (40 ml), was added potassium carbonate (7.77 g, 56.2 mmol) followed by
methyl 2-chloroacetate (CAS 96-34-4, 4.93 ml, 56.2 mmol) in acetonitrile (20 ml) dropwise. The
mixture was left stirring for 17h at room temperature. The reaction mixture was filtered and the
solid was washed with further acetonitrile (60 ml), the filtrate was concentrated in vacuo to yield
8.07 g (82%) of methyl 2-[(cyclopropylmethyl)amino]acetate (EV-AW6256-001) as a pale
yellow solid. LCMS (method D): retention time solvent front, M/z = 143.9 (M + 1).
[00227] Methyl 2-[N-(cyclopropylmethyl)-1-(1-methyl-1H-pyrazol-4-
yl)formamido]acetate EV-AW6260-002 – Step 2
[00228] Triethylamine (2.98 ml, 21.4 mmol) was added dropwise to a stirred solution of
methyl 2-[(cyclopropylmethyl)amino]acetate (EV-AW6256-001, 2.00 g, 10.2 mmol) in dry THF
(80 ml) at 0°C under an atmosphere of nitrogen and stirring was continued for 5 minutes. 1-
Methyl-1H-pyrazole-4-carbonyl chloride (CAS 79583-19-0, 1.62 g, 11.2 mmol) was added
portionwise to the reaction mixture at 0°C and stirring was continued for 1h at this temperature.
The reaction was quenched with water (80 ml) and the mixture was concentrated under reduced
pressure. The resulting aqueous residue was extracted with ethyl acetate (2 x 80 ml). The
combined organic layers were washed with saturated aqueous sodium chloride, dried over
sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by
column chromatography (0-5% methanol/DCM) to obtain 1.82 g (65%) of methyl 2-[N-
(cyclopropylmethyl)-1-(1-methyl-1H-pyrazol-4-yl)formamido]acetate (EV-AW6260-002) as a
pale yellow oil. LCMS (method D): retention time 0.86min, M/z = 252 (M + 1).
[00229] Sodium 2-[N-(cyclopropylmethyl)-1-(1-methyl-1H-pyrazol-4-
yl)formamido]acetate EV-AW6261-001 – Step 3
[00230] To methyl 2-[N-(cyclopropylmethyl)-1-(1-methyl-1H-pyrazol-4-
yl)formamido]acetate (EV-AW6260-002 and EV-AW6257-003 obtained as EV-AW6260-002,
2.23 g, 8.25 mmol) in THF (15 ml) was added 2M sodium hydroxide (10.3 ml). The reaction
mixture was heated at 50 °C with stirring for 2.5 h. The mixture was concentrated to dryness to
obtain 3.00 g (98%) of sodium 2-[N-(cyclopropylmethyl)-1-(1-methyl-1H-pyrazol-4-
yl)formamido]acetate (EV-AW6261-001). LCMS (method D): retention time 0.79min, M/z =
238 (M + 1).
[00231] 1-[1-(Cyclopropylmethyl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-5-yl]-2,2,2-
trifluoroethan-1-one EV-AW6265-002 – Step 4
[00232] To a stirred solution of sodium 2-[N-(cyclopropylmethyl)-1-(1-methyl-1H-pyrazol-4-
yl)formamido]acetate (EV-AW6261-001, 2.74 g, 7.40 mmol) in DCM (30 ml) was added
trifluoroacetic anhydride (4.12 ml, 29.6 mmol) at 0°C and the mixture was stirred at room
temperature for 2h. Further trifluoroacetic anhydride (4.12 ml, 29.6 mmol) at 0°C and stirring at
room temperature was continued for 17h. The solvent was removed in vacuo and the residue was
dissolved in DMF (50 ml), the mixture was cooled to 0°C and methanimidamide acetic acid
(2.31 g, 22.2 mmol) and potassium carbonate (3.07 g, 22.2 mmol) were added. The mixture was
heated at 70°C for 3h, diluted with water (30 ml) and extracted with ethyl acetate (2 x 30 ml).
The combined organic extracts were dried over sodium sulfate, filtered and concentrated in
vacuo. The residue was purified by column chromatography (0-75% ethyl acetate/heptane) to
obtain 1.32 g (60%) of 1-[1-(cyclopropylmethyl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-5-
yl]-2,2,2-trifluoroethan-1-one (EV-AW6265-002) as an off-white solid. LCMS (method D):
retention time 1.18min, M/z = 299 (M + 1).
[00233] 1-(Cyclopropylmethyl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-imidazole-5-carboxylic
acid EV-AW6268-002 – Step 5
[00234] To a solution of 1-[1-(cyclopropylmethyl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-
imidazol-5-yl]-2,2,2-trifluoroethan-1-one (EV-AW6265-002, 1.31 g, 4.08 mmol) in DMF (20
ml) under an atmosphere of nitrogen was added portionwise NaH (60%, 0.65 g, 16.3 mmol) with
ice-water cooling. The reaction mixture was heated at 70°C and stirred at this temperature for 3h.
The solvent was removed in vacuo and the residue was dissolved in water (60 ml) and acidified
to pH 4 with 1M HCl. The aqueous layer was extracted with a solution of 1:4 2-propanol:
chloroform (2 x 60 ml). The combined organic layers were dried over sodium sulfate, filtered
and concentrated under reduced pressure. The crude product and the concentrated aqueous layer
were purified by reverse phase chromatography (5-30% acetonitrile/water with 0.1% formic acid
additive) to obtain 0.90 g (89%)of 1-(cyclopropylmethyl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-
imidazole-5-carboxylic acid (EV-AW6268-002) as a creamy coloured solid. LCMS (method D):




(EOAI3482311) was synthesised according to the procedures described in Scheme 1 via
synthesis of methyl 2-cyclobutyl-1-ethyl-1H-imidazole-5-carboxylate (EV-AY4663-002) as
described in Scheme 1.17.
[00237] Scheme 1.17
[00238] Methyl 2-cyclobutyl-1-ethyl-1H-imidazole-5-carboxylate (EV-AY4663-002) –
Step 1
[00239] To a suspension of silver(1+) nitrate (161 mg, 0.95 mmol) and cyclobutanecarboxylic
acid (CAS 3721-95-7, 473 mg, 4.73 mmol) in 10% aqueous H2SO4 (15 ml) was added methyl 1-
ethyl-1H-imidazole-5-carboxylate (EV-AY4659-001, 243 mg, 1.58 mmol) and the reaction
mixture was heated at 70°C. A 0.2M aqueous solution of ammonium persulfate (23.6 ml) was
added in small portions during a period of 10 minutes. The reaction mixture was cooled down to
room temperature and was stirred for 10 minutes, poured into ice and basified using aqueous
ammonia ca. 33%, then extracted with ethyl acetate (2 x 20 ml). The combined extracts were
washed with saturated aqueous sodium chloride (2 x 20 ml), dried over magnesium sulfate and
concentrated in vacuo. The crude material was purified by flash column chromatography (5-50%
ethyl acetate/heptane) to obtain 72 mg (22%) of methyl 2-cyclobutyl-1-ethyl-1H-imidazole-5-
carboxylate (EV-AY4663-002) as a pale oil. LCMS (method D): retention time 0.82min, M/z =




112, EV-AY2080-001 (EOAI3655173) was synthesised according to the procedures described




yl]carbamate (EV-AY2075-002) – Step 1
[00244] To a solution of tert-butyl N-[(1R,4R,7R)-3-[2-[5-bromo-1-(cyclopropylmethyl)-6-
oxo-2-pyridyl]-7-methoxy-1-methyl-benzimidazole-5-carbonyl]-3-azabicyclo[2.2.1]heptan-7-
yl]carbamate (EV-AY2072-002 synthesised according to Scheme 1, 142 mg, 0.12 mmol) in
dioxane (1.5ml) and water (0.15 ml) was added methylboronic acid (CAS 10043-35-3, 14 mg,
0.23 mmol), tripotassium phosphate (19 µl, 0.23 mmol) and tricyclohexylphosphane (7 µl, 0.02
mmol). The reaction mixture was purged with nitrogen for 5 minutes and palladium(2+)
diacetate (3 mg, 0.01 mmol) was added in one portion. The reaction vessel was sealed and heated
to 120°C for 16h. The mixture was diluted with water (5 ml), extracted with DCM (2 x 15 ml).
The combined organics were concentrated and purified by column chromatography (0-10%
methanol /ethyl acetate) to obtain 37 mg (46%) of tert-butyl N-[(1R,4R,7R)-3-[2-[1-
(cyclopropylmethyl)-5-methyl-6-oxo-2-pyridyl]-7-methoxy-1-methyl-benzimidazole-5-
carbonyl]-3-azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AY2075-002) as a yellow oil. LCMS
(method D): retention time 1.15min, M/z = 562 (M + 1).
[00245] Tert-butyl N-[(1R,4R,7R)-3-[2-[1-(cyclopropylmethyl)-5-methyl-6-oxo-2-
pyridyl]-7-methoxy-1-methyl-benzimidazole-5-carbonyl]-3-azabicyclo[2.2.1]heptan-7-
yl]carbamate (EV-AY2080-001) – Step 2
[00246] Tert-butyl N-[(1R,4R,7R)-3-[2-[1-(cyclopropylmethyl)-5-methyl-6-oxo-2-pyridyl]-7-
methoxy-1-methyl-benzimidazole-5-carbonyl]-3-azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-
AY2075-002, 37 mg, 0.07 mmol) was dissolved in DCM (1ml) and treated with trifluoroacetic
acid (0.22 ml, 2.83 mmol) under an atmosphere of nitrogen and stirred at room temperature for
1h. The mixture was concentrated in vacuo and azeotroped with toluene/acetonitrile. The residue
was purified by prep HPLC (basic method), treated with Smopex-105 (5 mg) for 1 hour and
freeze dried to obtain 0.016 g (49%) of 6-[5-[(1R,4R,7R)-7-amino-3-azabicyclo[2.2.1]heptane-3-
carbonyl]-7-methoxy-1-methyl-benzimidazol-2-yl]-1-(cyclopropylmethyl)-3-methyl-pyridin-2-
one I-112 (EV-AY2080-001) as a white powder. LCMS (method H): retention time 2.28min,
M/z = 462 (M + 1).
[00247] I-118
[00248] (1R,4R,7R)-2-[2-(3-Ethylpyridin-4-yl)-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-
carbonyl]-2-azabicyclo[2.2.1]heptan-7-amine, I-118, EV-BA1121-001 (EOAI3694084) was
synthesised according to the procedures described in Scheme 1 via synthesis of methyl 3-
ethylpyridine-4-carboxylate (EV-BA1108-001) as described in Scheme 1.19.
[00249] Scheme 1.19
[00250] Methyl 3-ethenylpyridine-4-carboxylate (EV-BA1103-002) – Step 1
[00251] A suspension of methyl 3-bromopyridine-4-carboxylate (CAS 59786-31-1, 0.50 g,
2.31 mmol), caesium fluoride (1.05 g, 6.94 mmol) and 2,4,6-ethenylboroxin-pyridine complex
(CAS 95010-17-6, 1.39 g, 5.79 mmol) in THF (20 ml) was purged with nitrogen for 5 minutes.
Pd(dppf)Cl
2
(0.34 g, 0.46 mmol) was added and the reaction mixture was heated at 70°C for 2h.
The mixture was cooled down to room temperature and filtered through Celite washing the solid
with ethyl acetate. The filtrate was washed with saturated aqueous sodium chloride, dried over
magnesium sulfate, filtered and concentrated in vacuo. The residue was purified by column
chromatography (12-100% ethyl acetate/heptane) to obtain 0.37 g (97%) of methyl 3-
ethenylpyridine-4-carboxylate (EV-BA1103-002). LCMS (method D): retention time 0.88min,
M/z = 137 (M + 1).
[00252] Methyl 3-ethenylpyridine-4-carboxylate (EV-BA1108-001) – Step 2
[00253] A suspension of methyl 3-ethenylpyridine-4-carboxylate (EV-BA1103-002, 100 mg,
0.61 mmol) and Pd/C (10%, 33 mg, 0.03 mmol) in ethanol (2 ml) was stirred at room
temperature under an atmosphere of hydrogen for 16h. The reaction mixture was filtered
through Celite and the filtrate was concentrated to obtain 140 mg (55%) of methyl 3-
ethylpyridine-4-carboxylate (EV-BA1108-001). LCMS (method D): retention time 0.85min, M/z
= 166 (M + 1).
[00254] Scheme 2
[00255] Synthesis of (3R)-1-[1-methyl-2-(5-phenyl-1H-pyrazol-1-yl)-1H-1,3-
benzodiazole-5-carbonyl]piperidin-3-amine hydrochloride, I-59, EOAI3426751 (EV-
AO7894-001)
[00256] Methyl 1-methyl-2-oxo-2,3-dihydro- 1H-1,3-benzodiazole-5-carboxylate (EV-
AP4075-001) – Step 1
[00257] To a solution of methyl 3-amino-4-(methylamino)benzoate (EV-AN2487-001,
synthesised as described in Scheme 1, 100 mg, 0.54 mmol) in anhydrous DCM (3 ml) was added
1,1'-carbonyldiimidazole (110 mg, 0.68 mmol). The mixture was stirred at room temperature for
16h. The precipitate was collected by vacuum filtration and washed with ice-cold diethyl ether
(2x2 ml). The solid was air dried for 2h to obtain 82 mg (73%) of methyl 1-methyl-2-oxo-2,3-
dihydro- 1H-1,3-benzodiazole-5-carboxylate (EV-AP4075-001) as a white powder. LCMS
(method D): retention time 0.94min, M/z = 207 (M + 1).
[00258] Methyl 2-bromo-1-methyl-1H-1,3-benzodiazole-5-carboxylate (EV-AP4076-001)
– Step 2
[00259] To a solution of phosphorus oxybromide (217 mg, 0.76 mmol) in dichloroethane (3
ml) in a pressure tube was added methyl 1-methyl- 2-oxo-2,3-dihydro-1H-1,3-benzodiazole-5-
carboxylate (EV-AP4075-001, 78 mg, 0.38 mmol). The vessel was sealed and the mixture was
stirred at 80°C for 16h. The mixture was allowed to cool to room temperature and phosphorus
oxybromide (217 mg, 0.76 mmol) was added. The mixture was heated at 80°C for 5h then at
room temperature for 62h. Phosphorus oxybromide (434 mg, 1.52 mmol) was added and the
reaction heated at 80°C for 20h. The reaction was allowed to cool to room temperature and
neutralised with water (10 ml) and 2M aqueous sodium carbonate (10 ml). The aqueous mixture
was extracted with DCM (3x8 ml) and the combined organic extracts were washed with water
(3x5 ml), saturated aqueous sodium chloride (10 ml), dried over magnesium sulfate and
concentrated in vacuo to obtain 72 mg (68%) of methyl 2-bromo-1-methyl-1H-1,3-benzodiazole-
5-carboxylate (EV-AP4076-001) as a white powder. LCMS (method D): retention time 1.09min,
M/z = 269/271 (M + 1).
[00260] Methyl 1-methyl-2-(5-phenyl-1H-pyrazol-1-yl)-1H-1,3-benzodiazole-5-
carboxylate (EV-AQ1926-001) – Step 3
[00261] To a solution of methyl 2-bromo-1-methyl-1H-1,3-benzodiazole-5-carboxylate (EV-
AP4096-001, 57 mg, 0.20 mmol) in DMF (1 ml) in a pressure tube was added potassium
carbonate (56.2 mg, 0.41 mmol) followed by 3-phenyl-1H-pyrazole (CAS 2458-26-6, 44.0 mg,
0.31 mmol). The vessel was sealed and the reaction mixture was stirred at 120°C for 3h. The
mixture was allowed to cool to room temperature and partitioned between ethyl acetate (5 ml)
and water (5 ml). The aqueous layer was extracted with ethyl acetate (5 ml) then the combined
organic extracts were evaporated to dryness and azeotroped with heptane. The crude material
was purified by flash column chromatography (0 – 60% ethyl acetate/heptane) to obtain 24 mg
(35%) of methyl 1-methyl-2-(5-phenyl-1H-pyrazol-1-yl)-1H-1,3-benzodiazole-5-carboxylate
(EV-AQ1926-001) as a white solid. LCMS (method D): retention time 1.48min, M/z = 333 (M +
1).
[00262] 1-Methyl-2-(5-phenyl-1H-pyrazol-1-yl)-1H-1,3-benzodiazole-5-carboxylic acid
(EV-AO7889-001) – Step 4
[00263] To a solution of methyl 1-methyl-2-(5-phenyl-1H-pyrazol-1-yl)-1H-1,3-
benzodiazole-5-carboxylate (EV-AQ1926-001, 24 mg, 0.07 mmol) in THF/water (1:1, 4ml) was
added lithium hydroxide (6.0 mg, 0.25 mmol). The resulting mixture was stirred at 50°C for 2h.
The solvent was removed in vacuo to obtain 23 mg (assumed quantitive) of 1-methyl-2-(5-
phenyl-1H-pyrazol-1-yl)-1H-1,3-benzodiazole-5-carboxylic acid (EV-AO7889-001) as a white
solid. LCMS (method D): retention time 1.31min, M/z = 319 (M + 1).
[00264] Tert-butyl N-[(3R)-1-[1-methyl-2-(5-phenyl-1H-pyrazol-1-yl)-1H-1,3-
benzodiazole-5-carbonyl]piperidin-3-yl]carbamate (EV-AO7890-001) – Step 5
[00265] To a solution of 1-methyl-2-(5-phenyl-1H-pyrazol-1-yl)-1H-1,3-benzodiazole-5-
carboxylic acid (EV-AO7889-001, 22 mg, 0.07 mmol) and DIPEA (14 µl, 0.08 mmol) in
anhydrous DMF (3 ml) was added HATU (31 mg, 0.08 mmol). The reaction was stirred at room
temperature for 10 minutes, tert-butyl (3R)-piperidin-3-ylcarbamate (14 mg, 0.07 mmol) was
added and the reaction was continued for 60h. Further HATU (31 mg, 0.08 mmol), DIPEA (14
µl, 0.08 mmol) and tert-butyl (3R)-piperidin-3-ylcarbamate (14 mg, 0.07 mmol) were added. The
reaction was stirred at 60°C for 2.5h. The mixture was concentrated in vacuo and the residue was
purified by acidic HPLC preparative method to obtain 16 mg (47%) of tert-butyl N-[(3R)-1-[1-
methyl-2-(5-phenyl-1H-pyrazol-1-yl)-1H-1,3-benzodiazole-5-carbonyl]piperidin-3-yl]carbamate
(EV-AO7890-001) as a white powder.
[00266] (3R)-1-[1-Methyl-2-(5-phenyl-1H-pyrazol-1-yl)-1H-1,3-benzodiazole-5-
carbonyl]piperidin-3-amine hydrochloride, I-59, (EV-AO7894-001) – Step 6
[00267] 4M HCl in dioxane (2 ml) was added to a solution of tert-butyl N-[(3R)-1-[1-methyl-
2-(5-phenyl-1H-pyrazol-1-yl)-1H-1,3-benzodiazole-5-carbonyl]piperidin-3-yl]carbamate (EV-
AO7890-001, 16 mg, 0.03 mmol) in dioxane (2 ml) at room temperature. The mixture was
stirred at room temperature for 2h. The solvent was removed in vacuo and the residue was freeze
dried from acetonitrile:water (1:1, 2 ml) to obtain 14 mg (99%) of (3R)-1-[1-methyl-2-(5-phenyl-
1H-pyrazol-1-yl)-1H-1,3-benzodiazole-5-carbonyl]piperidin-3-amine hydrochloride, I-59, (EV-
AO7894-001) as a colourless crystalline solid. LCMS (method A): retention time 2.04min, M/z
= 401.2 (M + 1).
[00268] Scheme 3
[00269] 1-(Cyclopropylmethyl)-5-formyl-1H-pyrrole-2-carbonitrile (EV-AX5314-002) –
Step 1
[00270] To a solution of 5-formyl-1H-pyrrole-2-carbonitrile (CAS 81698-01-3, 749 mg, 6.24
mmol) in acetonitrile (25 ml) was added potassium carbonate (2.15 g, 15.6 mmol) followed by
(bromomethyl)cyclopropane (1.51 ml, 15.6 mmol). The mixture was stirred at 50°C for 17h. The
reaction mixture was cooled down to room temperature, poured onto water (75 ml) and extracted
with ethyl acetate (3 x 75 ml). The combined organic layers were washed with water (100 ml)
and saturated aqueous sodium chloride (100 ml), dried over sodium sulfate and concentrated in
vacuo. The crude product was purified by flash column chromatography (0-20% ethyl
acetate/heptane) to obtain 898 mg (79%) of 1-(cyclopropylmethyl)-5-formyl-1H-pyrrole-2-
carbonitrile as a white solid (EV-AX5314-002) as a white solid. LCMS (method D): retention
time 1.08min, M/z = 175 (M + 1).
[00271] Tert-butyl N-[(3R,6S)-1-[3-methoxy-4-(methylamino)-5-nitrobenzoyl]-6-
methylpiperidin-3-yl]carbamate (EV-AX5315-002) – Step 2
[00272] To a solution of 3-methoxy-4-(methylamino)-5-nitrobenzoic acid (CAS 1549812-23-
8, 264 mg, 1.17 mmol) and HATU (440 mg, 1.17 mmol) in dry DMF (5 ml) was added DIPEA
(0.41 ml, 2.33 mmol) and the mixture was stirred at room temperature for 30 minutes. Tert-butyl
N-[(3R,6S)-6-methylpiperidin-3-yl]carbamate (CAS 1227917-63-6, 250 mg, 1.17 mmol) was
added and the reaction stirred for 17h. The reaction mixture was concentrated in vacuo and
partitioned between ethyl acetate (50 ml) and saturated aqueous sodium chloride (50 ml). The
aqueous layer was extracted with ethyl acetate (30 ml) and the combined organics were washed
with water (40 ml), dried over sodium sulfate and concentrated in vacuo. The crude material was
purified by flash column chromatography (0-100% ethyl acetate/heptane) to obtain 421 mg
(85%) of tert-butyl N-[(3R,6S)-1-[3-methoxy-4-(methylamino)-5-nitrobenzoyl]-6-
methylpiperidin-3-yl]carbamate (EV-AX5315-002) as an orange foam. LCMS (method D):
retention time 1.18min, M/z = 423 (M + 1).
[00273] Tert-butyl N-[(3R,6S)-1-{2-[5-cyano-1-(cyclopropylmethyl)-1H-pyrrol-2-yl]-7-
methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-6-methylpiperidin-3-yl]carbamate
(EV-AX5316-002) – Step 3
[00274] To a mixture of tert-butyl N-[(3R,6S)-1-[3-methoxy-4-(methylamino)-5-
nitrobenzoyl]-6-methylpiperidin-3-yl]carbamate (EV-AX5315-002, 150 mg, 0.36 mmol) and 1-
(cyclopropylmethyl)-5-formyl-1H-pyrrole-2-carbonitrile (EV-AX5314-002, 64 mg, 0.37 mmol)
in ethanol (4 ml) was added portionwise a solution of sodium hydrosulfite (CAS 7775-14-6, 185
mg, 1.07 mmol) in water (2 ml). The mixture was purged with nitrogen and heated at 90°C for
17h. The reaction mixture was cooled down to room temperature and concentrated in vacuo.
DCM (30 ml) was added to the residue and the heterogeneous solution was dried over sodium
sulfate. The solid was filtered off and the filtrate was concentrated in vacuo. The crude material
was purified by preparative HPLC (acidic method) to obtain 143 mg (74%) of tert-butyl N-
[(3R,6S)-1-{2-[5-cyano-1-(cyclopropylmethyl)-1H-pyrrol-2-yl]-7-methoxy-1-methyl-1H-1,3-
benzodiazole-5-carbonyl}-6-methylpiperidin-3-yl]carbamate (EV-AX5316-002) as a white solid.
LCMS (method D): retention time 1.28min, M/z = 547 (M + 1).
[00275] EV-AX5316-002 was used to synthesise 5-{5-[(2S,5R)-5-amino-2-methylpiperidine-
1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrole-
2-carbonitrile, I-69, EV-AX5318-001 (EOAI3460934) according to the procedures described in
Scheme 1.




(cyclopropylmethyl)-1H-pyrrole-2-carbonitrile, I-73, EV-AX7827-001 (EOAI3461384) was







AX7819-001) – Step 1
[00281] Methyl-3-amino-5-methoxy-4-({[(1R,3S)-3-hydroxy-3-
methylcyclobutyl]methyl}amino)benzoate (EV-AX2006-001, 91%, 557 mg, 1.72 mmol) and 1-
(cyclopropylmethyl)-5-formyl-1H-pyrrole-2-carbonitrile (EV-AX5314-002, 300 mg, 1.72 mmol)
were dissolved in DMF (3 ml) and Na2S2O5 (982 mg, 5.17 mmol) was added. The reaction
mixture was stirred at 80°C for 17h and cooled down to room temperature. The mixture was
diluted with ethyl acetate (20 ml), washed with water (3 x 10 ml) and saturated aqueous sodium
chloride (5 ml). The combined organics were dried over sodium sulfate and concentrated in
vacuo. The crude was purified by flash column chromatography (0-100% ethyl acetate/heptane)
to obtain 574 mg (70%) of methyl-2-[5-cyano-1-(cyclopropylmethyl)-1H-pyrrol-2-yl]-7-
methoxy-1-{[(1R,3S)-3-hydroxy-3-methylcyclobutyl]methyl}-1H-1,3-benzodiazole-5-
carboxylate (EV-AX7819-001) as a yellow powder. LCMS (method D): retention time 1.19min,
M/z = 449 (M + 1).
[00282] Methyl-2-[5-cyano-1-(cyclopropylmethyl)-1H-pyrrol-2-yl]-7-methoxy-1-
{[(1R,3S)-3-methoxy-3-methylcyclobutyl]methyl}-1H-1,3-benzodiazole-5-carboxylate (EV-
AX7820-002) – Step 2
[00283] Methyl-2-[5-cyano-1-(cyclopropylmethyl)-1H-pyrrol-2-yl]-7-methoxy-1-{[(1R,3S)-
3-hydroxy-3-methylcyclobutyl]methyl}-1H-1,3-benzodiazole-5-carboxylate (EV-AX7819-001,
574 mg, 1.20 mmol) was dissolved in DMF (7 ml) and NaH (60%, 96 mg, 2.41 mmol) was
added. The reaction mixture was stirred at room temperature for 10 minutes then iodomethane
(374 µl, 6.01 mmol) was added. The reaction was stirred at room temperature for 4h then
concentrated in vacuo. The residue was diluted with water (20 ml) and extracted intoeEthyl
acetate (3 x 30 ml). The combined organics were dried over sodium sulfate and the evaporated to
dryness. The resulting material was purified by flash column chromatography (0-100% ethyl
acetate/heptane) then by preparative HPLC (acidic method) to obtain 282 mg (50%) of methyl-2-
[5-cyano-1-(cyclopropylmethyl)-1H-pyrrol-2-yl]-7-methoxy-1-{[(1R,3S)-3-methoxy-3-





001 (EOAI3468837) was synthesised according to procedures described in Scheme 3.1 via 1-
cyclopropyl-5-formyl-1H-pyrrole-2-carbonitrile EV-AY4323-001 synthesised as described in
Scheme 3.2.
[00286] Scheme 3.2
[00287] 1-Cyclopropyl-5-formyl-1H-pyrrole-2-carbonitrile (EV-AY4323-001) – Step 1
[00288] To a solution of 5-formyl-1H-pyrrole-2-carbonitrile (CAS 81698-01-3, 250 mg, 1.98
mmol), cyclopropylboronic acid (CAS 411235-57-9, 510 mg, 5.93 mmol) and Na2CO3 (629 mg,
5.93 mmol) in DCE (1 ml) was added a suspension of copper(II) diacetate (539 mg, 2.97 mmol)
and 2,2'-bipyridine (463 mg, 2.97 mmol) in DCE (2 ml). The reaction mixture was stirred at
70°C for 4h, cooled down to room temperature and quenched with 1M HCl (15 ml). The
resulting material was extracted with ethyl acetate (3 x 10 ml). The combined organic fractions
were washed with 5N NaOH (10 ml), saturated aqueous sodium chloride (10 ml), dried over
sodium sulphate and concentrated in vacuo. The crude was purified by flash column
chromatography (eluting with 0-50% ethyl acetate/heptane) to obtain 120 mg (38%) of 1-
cyclopropyl-5-formyl-1H-pyrrole-2-carbonitrile (EV-AY4323-001) as a white powder. LCMS




AY4338-001 (EOAI3468838) was synthesised according to the procedures described in Scheme
3 via synthesis of 5-formyl-1-(2,2,2-trifluoroethyl)-1H-pyrrole-2-carbonitrile EV-AY4332-001
as described in Scheme 3.3
[00291] Scheme 3.3
[00292] 5-Formyl-1-(2,2,2-trifluoroethyl)-1H-pyrrole-2-carbonitrile (EV-AY4332-001) –
Step 1
[00293] To a solution of 5-formyl-1H-pyrrole-2-carbonitrile (CAS 81698-01-3, 300 mg, 2.37
mmol) in DMF (10 ml) were added NaH (60%, 114 mg, 2.85 mmol) and 2,2,2-trifluoroethyl
trifluoromethanesulfonate (582 µl, 4.03 mmol). The reaction was stirred at room temperature for
20h. The reaction mixture was diluted with water (10 ml) and extracted with ethyl acetate (3 x 10
ml). The organic extracts were combined and washed with 5N NaOH (10 ml), saturated aqueous
sodium chloride (10 ml), dried over sodium sulfate and concentrated in vacuo. The crude was
purified by flash column chromatography (0-50% ethyl acetate/heptane) to obtain 406 mg (85%)
of 5-formyl-1-(2,2,2-trifluoroethyl)-1H-pyrrole-2-carbonitrile (EV-AY4332-001) as a white




AY4530-001 (EOAI3469925) was synthesised according to the procedures described in Scheme
3 via synthesis of 1-(cyclopropylmethyl)-2-phenyl-1H-imidazole-5-carbaldehyde (EV-AW6299-
002) as described in Scheme 3.4.
[00296] Scheme 3.4
[00297] N'-(Cyclopropylmethyl)benzenecarboximidamide (EV-AW6298-001) – Step 1
[00298] To a solution of cyclopropylmethanamine (CAS 2516-47-4, 276 mg, 3.88 mmol) and
benzonitrile (CAS 100-47-0, 400 mg, 3.88 mmol) in THF (8 ml) was slowly added 1,4-
diazabicyclo[2.2.2]octane - trimethylaluminum (1:2) (994 mg, 3.88 mmol). The reaction mixture
was heated to 130°C under microwave condition for 6h. The reaction was cooled down to 0°C
and slowly quenched with ethyl acetate (40 ml). Saturated Rochelle salt solution was added and
the organic layer was separated, dried over magnesium sulfate, filtered and concentrated to
obtain 594 mg (88%) of N'-(cyclopropylmethyl)benzenecarboximidamide (EV-AW6298-001) as
a colourless oil. LCMS (method D): retention time 0.66min, M/z = 174 (M + 1).
[00299] 1-(Cyclopropylmethyl)-2-phenyl-1H-imidazole-5-carbaldehyde (EV-AW6299-
002) – Step 2
[00300] A mixture of isopropanol (4 ml), (Z)-N'-(cyclopropylmethyl)benzene-1-
carboximidamide (EV-AW6298-001, 594 mg, 3.41 mmol), triethylamine (0.44 ml, 3.14 mmol)
and acetic acid (205 µl, 3.58 mmol) was stirred for 5 minutes at room temperature.
Bromopropanedial (CAS 2065-75-0, 514 mg, 3.41 mmol) in isopropanol (4 ml) was added
dropwise and the reaction mixture was heated for 16h at 80°C. The reaction mixture was cooled
down to room temperature and retreated with further bromopropanedial (154 mg, 1.02 mmol)
and stirring at 80°C was continued for 3h. The solvent was evaporated, the residue was diluted
with water (25 ml) and extracted with ethyl acetate (2 x 25 ml). The combined organic phases
were dried over sodium sulfate, filtered and concentrated. The residue was purified by flash
chromatography (10-70% ethyl acetate/heptane) to obtain 173 mg (20%) of 1-
(cyclopropylmethyl)-2-phenyl-1H-imidazole-5-carbaldehyde (EV-AW6299-002) as an orange




pyrrole-2-carbonitrile, I-89, EV-AY4541-001 (EOAI3470261) was synthesised according to the
procedures described in Scheme 3 via synthesis of 5-formyl-1-[(3-hydroxy-3-
methylcyclobutyl)methyl]-1H-pyrrole-2-carbonitrile (EV-AZ4535-001) as described in Scheme
3.5.
[00303] Scheme 3.5
[00304] Methyl (1R,3S)-3-hydroxy-3-methylcyclobutane-1-carboxylate (EV-AY4513-
002) – Step 1
[00305] To a solution of methyl 3-oxocyclobutane-1-carboxylate (CAS 695-95-4, 4.00 g, 31.2
mmol) in THF (100 ml) at -78°C, was added 1M methyl magnesium bromide in THF (35.9 ml,
35.9 mmol). The mixture was stirred at -78°C for 2h then allowed to warm to room temperature
and stirred for 16h. The reaction mixture was cooled down to -78°C and a saturated solution of
ammonium chloride (10 ml) was added. The resulting mixture was diluted with water (200 ml)
and extracted with ethyl acetate (2 x 200 ml). The combined organic extracts were dried over
sodium sulfate, filtered and concentrated. The residue was purified by column chromatography
(0-100% ethyl acetate/heptane) to obtain 2.05 g (46%) of methyl (1R,3S)-3-hydroxy-3-
methylcyclobutane-1-carboxylate (EV-AY4513-002) as a colourless oil. 1H NMR (500 MHz,
Chloroform-d) δ 3.70 – 3.68 (m, 3H), 2.74 – 2.64 (m, 1H), 2.40 – 2.25 (m, 4H), 1.41 – 1.36 (m,
3H). No LCMS data. No LCMS data.
[00306] (1R,3S)-3-(Hydroxymethyl)-1-methylcyclobutan-1-ol (EV-AY4522-001) – Step 2
[00307] To methyl (1R,3S)‐3‐methoxy‐3‐methylcyclobutane‐1‐carboxylate (EV-AY4513-
002, 250 mg, 1.73 mmol) and sodium hydride (60%, 73 mg, 1.82 mmol) was added dry DMF (3
ml) at 0°C and the mixture was stirred at 0°C for 15 minutes. Methyl iodide (0.22 ml,
3.47 mmol) was added, the mixture was warmed up to room temperature and stirred for 48h. The
reaction mixture was partitioned between ethyl acetate (80 ml) and water (80 ml). The aqueous
extract was washed with further ethyl acetate (80 ml), the combined organic extracts were dried
over sodium sulfate, filtered and concentrated. The residue was diluted with THF (3 ml) and
methanol (0.3 ml) and sodium borohydride (197 mg, 5.20 mmol) was added. The mixture was
stirred at room temperature for 16h, concentrated in vacuo and purified by column
chromatography (0-100% ethyl acetate/heptane) to obtain 107 mg (48%) of [(1R,3S)-3-methoxy-
3-methylcyclobutyl]methanol (EV-AY4522-001) as a colourless oil. 1H NMR (500 MHz,
Chloroform-d) δ 3.63 (d, J = 6.2 Hz, 2H), 3.16 (s, 3H), 2.17 – 2.09 (m, 1H), 2.03 – 1.97 (m, 2H),
1.89 – 1.81 (m, 2H), 1.33 (s, 3H). No LCMS data.
[00308] [(1R,3S)-3-Methoxy-3-methylcyclobutyl]methyl 4-methylbenzene-1-sulfonate
(EV-AY4533-001) – Step 3
[00309] To a solution of [(1R,3S)-3-methoxy-3-methylcyclobutyl]methanol (EV-AY4529-
001, 305 mg, 1.76 mmol) in DCM (10 ml) with ice cooling were added triethylamine (0.32 ml,
2.28 mmol), DMAP (11 mg, 0.088 mmol) and 4-methylbenzene-1-sulfonyl chloride (352 mg,
1.84 mmol). The reaction mixture was allowed to warm to room temperature and stirred for 4h.
The mixture was partitioned between DCM (30 ml) and water (30 ml). The organic extract was
dried over sodium sulfate, filtered and concentrated to obtain 480 mg (96%) of [(1R,3S)-3-
methoxy-3-methylcyclobutyl]methyl 4-methylbenzene-1-sulfonate (EV-AY4533-001) as a
viscous colourless oil. LCMS (method D): retention time 1.29min, M/z = 307 (M + 23).
[00310] 5-Formyl-1-{[(1R,3S)-3-methoxy-3-methylcyclobutyl]methyl}-1H-pyrrole-2-
carbonitrile (EV-AY4535-001) – Step 4
[00311] To a solution of 5-formyl-1H-pyrrole-2-carbonitrile (EV-AY4533-001, 100 mg, 0.83
mmol) in acetonitrile (2 ml) was added potassium carbonate (288 mg, 2.08 mmol) followed by
[(1R,3S)-3-methoxy-3-methylcyclobutyl]methyl 4-methylbenzene-1-sulfonate (EV-AY4533-
001, 272 mg, 0.96 mmol). The mixture was stirred at 60°C for 16h, heated at 80°C and left
stirring at this temperature for 6h. The mixture was poured into water (30 ml) and extracted with
ethyl acetate (2 x 30 ml). The combined organic layers were dried over sodium sulfate, filtered
and concentrated. The mixture was then retreated with potassium carbonate (288 mg, 2.08 mmol)
and acetonitrile (2 ml) and stirred at 80°C for 24h. The mixture was poured into water (30 ml)
and extracted with DCM (2 x 30 ml). The combined organic layers were washed with 2M NaOH
(20 ml), dried over sodium sulfate, filtered and concentrated. The residue was purified by
column chromatography (0-60% ethyl acetate/heptane) to obtain 68 mg (35%) of 5-formyl-1-
{[(1R,3S)-3-methoxy-3-methylcyclobutyl]methyl}-1H-pyrrole-2-carbonitrile (EV-AY4535-001)




(EOAI3476158) was synthesised according to the procedures described in Scheme 3.6 via
synthesis of tert-butyl N-[(1R,4R,7R)-2-[7-methoxy-1-methyl-2-(6-oxo-1,6-dihydropyridin-2-
yl)-1H-1,3-benzodiazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AY2038-




AY2040-001) – Step 1
[00316] Tert-butyl N-[(1R,4R,7R)-2-[7-methoxy-1-methyl-2-(6-oxo-1,6-dihydropyridin-2-yl)-
1H-1,3-benzodiazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-7-yl]carbamate (137 mg, 0.25
mmol) was dissolved in dry DMF (2ml) under an atmosphere of nitrogen and treated with
Cs2CO3 (98 mg, 0.30 mmol). The resulting mixture was stirred at room temperature for 2-3
minutes, (bromomethyl)cyclopropane (CAS 7051-34-5, 27 µl, 0.27 mmol) was added in one
portion and the reaction mixture was stirred at room temperature for 16h. The mixture was
diluted with water (10 ml), saturated ammonium chloride (6 ml) and extracted with ethyl acetate
(3 x 20 ml). The combined organic extracts were dried over sodium sulfate, filtered and
concentrated. The residue was purified by column chromatography (0-15% methanol/DCM) to
obtain 184 mg of tert-butyl N-[(1R,4R,7R)-2-{2-[6-(cyclopropylmethoxy)pyridin-2-yl]-7-
methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-yl]carbamate
(EV-AY2040-001) as a pale yellow glass. LCMS (method D): retention time 1.32min, M/z =
548 (M + 1).
[00317] Tert-butyl N-[(1R,4R,7R)-2-[7-methoxy-1-methyl-2-(6-oxo-1,6-dihydropyridin-2-
yl)-1H-1,3-benzodiazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-
AY2043-002) – Step 2
[00318] Tert-butyl N-[(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-oxo-1,6-dihydropyridin-2-
yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-
yl]carbamate (EV-AY2040-001, 76%, 184 mg, 0.26 mmol) was dissolved in DCM (4ml) under
an atmosphere of nitrogen at room temperature and treated with trifluoroacetic acid (0.6 ml). The
mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated and
purified by prep HPLC (acidic method) to obtain 27 mg (23%) of (1R,4R,7R)-2-{2-[6-
(cyclopropylmethoxy)pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-
azabicyclo[2.2.1]heptan-7-amine (EV-AY2043-002) as a white glass/foam. LCMS (method A):




AY2061-002 (EOAI3477377) was synthesised according to the procedures described in Scheme
3 via synthesis of 5-formyl-1-[(3-hydroxy-3-methylcyclobutyl)methyl]-1H-pyrrole-2-carbonitrile
(EV-AY2050-001) as described in Scheme 3.7.
[00321] Scheme 3.7
[00322] 1-(Cyclopropylmethyl)-6-oxo-1,6-dihydropyridine-2-carbaldehyde (EV-AY2050-
001) – Step 1
[00323] 6-Oxo-1,6-dihydropyridine-2-carbaldehyde (CAS 358751-77-6, 294 mg, 2.39 mmol)
was dissolved in dry DMSO (10 ml) under an atmosphere of nitrogen and treated with Cs2CO3
(934 mg, 2.87 mmol) and (bromomethyl)cyclopropane (CAS 7051-34-5, 0.25 ml, 2.63 mmol).
The reaction mixture was stirred at room temperature for 16h, diluted with water (20 ml) and
extracted with ethyl acetate (3 x 20ml). The combined organic extracts were washed with water,
saturated aqueous sodium chloride, dried over sodium sulfate, filtered and concentrated. The
residue was purified by column chromatography (10-100% ethyl acetate/heptane) to obtain 0.16
g (38%) of 1-(cyclopropylmethyl)-6-oxo-1,6-dihydropyridine-2-carbaldehyde (EV-AY2050-
001) as a dark green gum, LCMS (method D): retention time 0.92min, M/z = 178 (M + 1), and
0.21 g of 6-(cyclopropylmethoxy)pyridine-2-carbaldehyde (EV-AY2050-002) as a colourless oil,




(EOAI3478191) was synthesised from the Boc deprotection of tert-butyl N-[(1R,4R,7R)-2-[2-
(2-ethyl-5-methyl-1-phenyl-1H-pyrrol-3-yl)-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-
carbonyl]-2-azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AY2064-001) as described in Scheme
3.8.
[00326] Scheme 3.8
[00327] Ethyl 2-propanoylpent-4-enoate (EV-AY2058-002) – Step 1
[00328] Ethyl 3-oxopentanoate (CAS 4949-44-4, 500 mg, 3.47 mmol) was dissolved in dry
DMF (2.5ml) under an atmosphere of nitrogen and the resulting mixture was cooled to 0°C. The
reaction mixture was treated with sodium hydride (60%, 166 mg, 4.16 mmol) and stirred at 0°C
for 30 minutes then 3-bromoprop-1-ene (CAS 106-95-6, 360 µl, 4.16 mmol) was added
dropwise over 10 minutes. The reaction mixture was allowed to warm to room temperature and
stirred for 17h then diluted with water (20 ml) and extracted with TBME (3 x 25 ml). The
combined organics were washed with saturated aqueous sodium chloride (30 ml), dried over
sodium sulfate and concentrated in vacuo. The crude product was purified by flash column
chromatography (0-5% ethyl acetate/heptane) to obtain 341 mg (49%) of ethyl 2-propanoylpent-
4-enoate (EV-AY2058-002) as a colourless oil. LCMS (method D): retention time 1.21min,
mass ion not observed.
[00329] Ethyl 2-ethyl-5-methyl-1-phenyl-1H-pyrrole-3-carboxylate (EV-AY2062-001) –
Step 2
[00330] Ethyl 2-propanoylpent-4-enoate (EV-AY2058-002, 341 mg, 1.68 mmol) was
dissolved in dry toluene (3ml) and aniline (77 µl, 0.84 mmol) and palladium(II)
bis(trifluoroacetate) (28 mg, 0.08 mmol) were added. The reaction mixture was stirred at 60°C
for 18h, cooled down to room temperature, diluted with ethyl acetate (5 ml) and filtered through
a pad of Kieselguhr, washing with ethyl acetate (30 ml). The filtrate was concentrated in vacuo
and purified by flash column chromatography (0-40% ethyl acetate/heptane) to obtain 313 mg
(38%) of ethyl 2-ethyl-5-methyl-1-phenyl-1H-pyrrole-3-carboxylate (EV-AY2062-001) as a pale
yellow oil. LCMS (method D): retention time 1.34min, M/z = 258 (M + 1).
[00331] 2-Ethyl-5-methyl-1-phenyl-1H-pyrrole-3-carboxylic acid (EV-AY2063-001) –
Step 3
[00332] 1M aqueous NaOH (0.95 ml) was added to a solution of ethyl 2-ethyl-5-methyl-1-
phenyl-1H-pyrrole-3-carboxylate (EV-AY2062-001, 313 mg, 0.63 mmol) in methanol (5 ml)
and the resultant mixture was stirred at 50°C for 2h. Further 1M NaOH (0.95 ml) was added and
the mixture was stirred at 60°C for 16h then 80°C for 20h. The reaction mixture was allowed to
cool to room temperature and concentrated in vacuo. Water (7 ml) was added then 1N HCl until
pH 2. The resulting precipitate was filtered off, washed with water (2 x 3 ml) and dried to obtain
87 mg (58%) of 2-ethyl-5-methyl-1-phenyl-1H-pyrrole-3-carboxylic acid (EV-AY2063-001) as
a pale beige solid. LCMS (method D): retention time 0.86min, M/z = 230 (M + 1).
[00333] Tert-butyl N-[(1R,4R,7R)-2-[2-(2-ethyl-5-methyl-1-phenyl-1H-pyrrol-3-yl)-7-
methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-7-
yl]carbamate (EV-AY2064-001) – Step 4
[00334] 2-Ethyl-5-methyl-1-phenyl-1H-pyrrole-3-carboxylic acid (EV-AY2063-001, 87 mg,
0.36 mmol) was dissolved in DMF (1ml) under an atmosphere of nitrogen and treated with
HATU (166 mg, 0.44 mmol) and DIPEA (76 µl, 0.44 mmol). The reaction mixture was stirred at
room temperature for 15 minutes then tert-butyl N-[(1R,4R,7R)-2-[3-amino-5-methoxy-4-
(methylamino)benzoyl]-2-azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AY8858-001,
synthesised according to the procedures described in Scheme 5, 142 mg, 0.36 mmol) was added
and the reaction stirred at room temperature for 2.5h then 50°C for 2h. The reaction was left
standing at room temperature for 18h then stirred at 40°C for 22h. The reaction mixture was
concentrated in vacuo and azeotroped with toluene (5 ml). The crude material was purified by
flash column chromatography (50-100% ethyl acetate/heptane) to obtain tert-butyl N-
[(1R,4R,7R)-2-[2-(2-ethyl-5-methyl-1-phenyl-1H-pyrrol-3-yl)-7-methoxy-1-methyl-1H-1,3-
benzodiazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AY2064-001) as a
yellow glassy solid. LCMS (method D): retention time 1.19min, M/z = 584 (M + 1).





AY2057-002 (EOAI3476817) were obtained via Boc deprotection of tert‐butyl
N‐[(1R,4R,7R)‐2‐[2‐(1‐benzyl‐2‐ethyl‐1H‐pyrrol‐3‐yl)‐7‐methoxy‐1‐methyl‐1H‐1,3‐benzodiazol
e‐5‐carbonyl]‐2‐azabicyclo[2.2.1]heptan‐7‐yl]carbamate (EV-AY2054-002) and tert-butyl N-
benzyl-N-[(1R,4R,7R)-2-[2-(1-benzyl-2-ethyl-1H-pyrrol-3-yl)-7-methoxy-1-methyl-1H-1,3-
benzodiazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AY2054-003)
respectively. These were synthesised according to the procedures described in Scheme 4.
[00337] Scheme 4
[00338] N-[(1E)-furan-3-ylmethylidene]-4-methylbenzene-1-sulfonamide (EV-AY2033-
006) – Step 1
[00339] 4-Methylbenzenesulfonamide (CAS 70-55-3, 1.00 g, 5.84 mmol) and furan-3-
carbaldehyde (CAS 498-60-2, 0.49 ml, 5.84 mmol) were suspended in tetraethyl orthosilicate
(1.43 ml, 6.42 mmol). The vessel was sealed and heated to 160°C for 4h. The reaction was
cooled down to room temperature and diluted with diethyl ether (4 ml), stirred and filtered to
obtain 0.81 g (52%) of N-[(1E)-furan-3-ylmethylidene]-4-methylbenzene-1-sulfonamide (EV-
AY2033-006) as a brown solid. LCMS (method D): retention time 1.12min, M/z = 250 (M + 1).
[00340] 2-Ethyl-1-(4-methylbenzenesulfonyl)-1H-pyrrole-3-carbaldehyde (EV-AY2041-
001) – Step 2
[00341] 3M Bromo(ethyl)magnesium (1.90 ml) was added dropwise over 5 minutes to a
stirred solution of N-[(1E)-furan-3-ylmethylidene]-4-methylbenzene-1-sulfonamide (EV-
AY2033-006, 604 mg, 2.28 mmol) in dry THF (10 ml) at 0°C under an atmosphere of nitrogen.
The mixture was left stirring at room temperature for 3h then cooled to 0°C and treated with 1M
HCl in water (5.7ml). The reaction was diluted with THF (15 ml) and 1-bromopyrrolidine-2,5-
dione (405 mg, 2.28 mmol) was added in one portion. The reaction mixture was stirred at room
temperature for 16h, diluted with saturated ammonium chloride (12ml) and water (5ml) and
extracted with ethyl acetate. The combined organics were washed with saturated aqueous sodium
chloride, dried over sodium sulfate, filtered and concentrated. The residue was purified by
column chromatography (10-20% ethyl acetate/heptane) to obtain 348 mg (47%) of 2-ethyl-1-(4-
methylbenzenesulfonyl)-1H-pyrrole-3-carbaldehyde (EV-AY2041-001) as a colourless oil.
LCMS (method D): retention time 1.32min, M/z = 278 (M + 1).
[00342] 2-Ethyl-1-(4-methylbenzenesulfonyl)-1H-pyrrole-3-carbaldehyde (EV-AY2044-
002) – Step 3
[00343] Tert-butyl N-[(1R,4R,7R)-2-[3-methoxy-4-(methylamino)-5-nitrobenzoyl]-2-
azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AY4011-002 synthesised according to Scheme 5
steps 1-3, 0.78 g, 1.57 mmol) and 2-ethyl-1-(4-methylbenzenesulfonyl)-1H-pyrrole-3-
carbaldehyde (EV-AY2041-001, 0.43 g, 1.56 mmol) were dissolved in ethanol (15ml) and water
(7.5ml). Disodium dithionite (2.45 g, 14.1 mmol) was added in one portion and the reaction
mixture was stirred at 90°C for 4h. The mixture was cooled to room temperature, diluted with
water (15 ml) and extracted with ethyl acetate. The combined organics were washed with
saturated aqueous sodium chloride, dried over sodium sulfate, filtered and concentrated in vacuo.
The residue was purified by column chromatography (0-5% methanol/DCM) to obtain 0.71 g of
tert-butyl N-[(1R,4R,7R)-2-{2-[2-ethyl-1-(4-methylbenzenesulfonyl)-1H-pyrrol-3-yl]-7-
methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-yl]carbamate







yl]carbamate (EV-AY2044-002, 573 mg, 0.8 mmol) was dissolved in dry THF (15ml) under an
atmosphere of nitrogen and treated with 1M N,N,N-tributylbutan-1-aminium fluoride in THF
(2.39 ml). The mixture was stirred at room temperature for 16h then at 40°C for 5h. Further 1M
N,N,N-tributylbutan-1-aminium fluoride in THF (1.1ml) was added and stirring at 50°C was
continued for 16h. The mixture was diluted with saturated ammonium chloride (20 ml) and
extracted with ethyl acetate. The combined organics were washed with saturated aqueous sodium
chloride, dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified
by column chromatography (0-10% methanol/DCM) followed by purification on SCX-2
cartridge to obtain 313 mg of (77%) of tert-butyl N-[(1R,4R,7R)-2-[2-(2-ethyl-1H-pyrrol-3-yl)-
7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-7-
yl]carbamate (EV-AY2049-003) as a pink beige solid. LCMS (method D): retention time
1.03min, M/z = 494 (M + 1).
[00346] Tert-butyl N-[(1R,4R,7R)-2-[2-(1-benzyl-2-ethyl-1H-pyrrol-3-yl)-7-methoxy-1-
methyl-1H-1,3-benzodiazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-
AY2054-002) and tert-butyl N-benzyl-N-[(1R,4R,7R)-2-[2-(1-benzyl-2-ethyl-1H-pyrrol-3-
yl)-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-7-
yl]carbamate (EV-AY2054-003) – Step 5
[00347] Tert-butyl N-[(1R,4R,7R)-2-[2-(2-ethyl-1H-pyrrol-3-yl)-7-methoxy-1-methyl-1H-
1,3-benzodiazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AY2049-003, 100
mg, 0.19 mmol) was dissolved in dry DMF (2 ml) under an atmosphere of nitrogen and cooled to
0°C. The reaction mixture was treated with sodium hydride (60%, 11 mg, 0.27 mmol) in one
portion and stirred at 0°C for 15 minutes. The reaction mixture was treated with
(bromomethyl)benzene (CAS 100-39-0, 23 µl, 0.19 mmol) and stirred for a further 3h at room
temperature. The mixture was diluted with saturated ammonium chloride (12 ml) and water (3
ml), heptane (8 ml) was added, the mixture was stirred and filtered and the solid was purified by
column chromatography (0-5% methanol/ethyl acetate) to obtain 74 mg (57%) of tert-butyl N-
[(1R,4R,7R)-2-[2-(1-benzyl-2-ethyl-1H-pyrrol-3-yl)-7-methoxy-1-methyl-1H-1,3-benzodiazole-
5-carbonyl]-2-azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AY2054-002) as a pale yellow glass,
LCMS (method D): retention time 1.24min, M/z = 584 (M + 1).
[00348] 21 mg (15.1%) of tert-butyl N-benzyl-N-[(1R,4R,7R)-2-[2-(1-benzyl-2-ethyl-1H-
pyrrol-3-yl)-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-
7-yl]carbamate (EV-AY2054-003) were also isolated as a pale yellow glass. LCMS (method D):
retention time 1.37min, M/z = 674 (M + 1).
[00349] Scheme 5
[00350] Methyl 3-methoxy-4-(methylamino)-5-nitrobenzoate (EV-AX9482-002) – Step 1
[00351] Potassium carbonate (11.3 g, 81.4 mmol) and 2 M MeNH2 in THF (61 ml) were
added at room temperature to a stirred solution of methyl 4-chloro-3-methoxy-5-nitrobenzoate
(CAS 63603-09-8, 10.0 g, and 40.71 mmol) in THF (180 ml). The resulting mixture was stirred
at 60°C for 24 h and concentrated in vacuo. The residue was re-dissolved in ethyl acetate (500
ml), washed with water (2 × 250 ml) and saturated aqueous sodium chloride (200 ml). The
organic extracts were dried over sodium sulfate and concentrated in vacuo to afford 9.38 g (96%)
of methyl 3-methoxy-4-(methylamino)-5-nitrobenzoate (EV-AX9482-001) as an orange powder.
LCMS (method D): retention time 1.30min, M/z = 241 (M + 1).
[00352] 3-Methoxy-4-(methylamino)-5-nitrobenzoic acid (EV-AX9487-001) – step 2
[00353] 2M aqueous LiOH (58.2 ml) was added to a solution of methyl 3-methoxy-4-
(methylamino)-5-nitrobenzoate (EV-AX9482-002, 9.32 g, 38.8 mmol) in THF:methanol (4:1)
(75 ml) and the resulting mixture was stirred at 50°C for 5 h. The reaction mixture was
concentrated in vacuo, re-dissolved in water (50 ml, and acidified to pH 2 using 2 M aqueous
HCl. The precipitate was filtered under vacuum to afford 9.75g (quantitative) of 3-methoxy-4-
(methylamino)-5-nitrobenzoic acid (EV-AX9487-001) as a bright orange powder. LCMS
(method D): retention time 1.01min, M/z = 227 (M + 1).
[00354] Tert-butyl N-[(1R,4R,7R)-2-[3-methoxy-4-(methylamino)-5-nitrobenzoyl]-2-
azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AX9493-002) – Step 3
[00355] DIPEA (6.58 ml, 39.79 mmol) and HATU (11.4 g, 29.8 mmol) were added to a
solution of 3-methoxy-4-(methylamino)-5-nitrobenzoic acid (EV-AX9487-001, 90%, 5.00 g,
19.9 mmol) in DMF (60 ml) and the resulting mixture was stirred at room temperature for 10
minutes. Tert‐butyl N‐[(1R,4R,7R)‐2‐azabicyclo[2.2.1]heptan‐7‐yl]carbamate (EV-AX2051-
001, 4.43 g, 20.89 mmol) (synthesised as in Adv. Synth. Catal. 2005, 347, 1242 – 1246) was
added to the reaction mixture and stirring at room temperature was continued for 2h. The
reaction mixture was concentrated in vacuo and the resulting residue was dissolved in ethyl
acetate (250 ml), washed with water (2 × 100 ml) and saturated aqueous sodium chloride (100
ml). The organic extracts were dried over sodium sulfate, concentrated in vacuo and purified by
flash column chromatography (0-100% ethyl acetate/heptane) to obtain 6.39 g (76%) of tert-
butyl N-[(1R,4R,7R)-2-[3-methoxy-4-(methylamino)-5-nitrobenzoyl]-2-azabicyclo[2.2.1]heptan-
7-yl]carbamate (EV-AX9493-002) as a red powder. LCMS (method D): retention time 1.19min,
M/z = 421 (M + 1).
[00356] Tert-butyl N-[(1R,4R,7R)-2-[3-amino-5-methoxy-4-(methylamino)benzoyl]-2-
azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AY8858-001) – Step 4
[00357] Na2 S2 O4 (85%, 14.6 g, 71.4 mmol) was added to a solution of tert-butyl N-
[(1R,4R,7R)-2-[3-methoxy-4-(methylamino)-5-nitrobenzoyl]-2-azabicyclo[2.2.1]heptan-7-
yl]carbamate (EV-AX9493-002, 3.00 g, 7.14 mmol) in ethanol (20 ml) and water (10 ml) and the
resulting mixture was stirred at 90°C for 3 h. The reaction mixture was diluted with water (50
ml) and the resulting solution was extracted with ethyl acetate (2 × 100 ml). The combined
organic extracts were dried over sodium sulfate and concentrated in vacuo to afford 2.71 g (97%)
of tert-butyl N-[(1R,4R,7R)-2-[3-amino-5-methoxy-4-(methylamino)benzoyl]-2-
azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AY8858-001) as an off-white powder. LCMS
(method D): retention time 0.82min, M/z = 391 (M + 1).
[00358] Scheme 6
[00359] Methyl 2-ethylpyridine-3-carboxylate (EV-AY8832-002) – Step 1
[00360] Pd(dppf)Cl
2
(299 mg, 0.41 mmol) and 1M diethylzinc in hexane (4.9 ml) were added
to a solution of methyl 2-chloropyridine-3-carboxylate (CAS 2942-59-8, 532 µl, 4.08 mmol) in
dry dioxane (7 ml) and the resulting mixture was stirred under nitrogen at 60°C for 2 h. The
reaction mixture was diluted with water (20 ml) and extracted with ethyl acetate (3 × 50 ml). The
combined organic extracts were dried over sodium sulfate, concentrated in vacuo and purified by
column chromatography (0-100% ethyl acetate/heptane) to afford 647 mg (96%) of methyl 2-
ethylpyridine-3-carboxylate (EV-AY8832-002) as a colourless volatile oil. LCMS (method D):
retention time 0.79min, M/z = 166 (M + 1).
[00361] 2-Ethylpyridine-3-carboxylic acid (EV-AY8835-001) – Step 2
[00362] 1M aqueous NaOH (5.51 ml) was added to a solution of methyl 2-ethylpyridine-3-
carboxylate (EV-AY8832-002, 607 mg, 3.67 mmol) in methanol (5 ml) and the resulting mixture
was stirred at 50°C for 2h. The reaction mixture was concentrated in vacuo, the residue was
dissolved in water (10 ml) and acidified to pH 3 using 2 M aqueous HCl solution. The solution
was extracted with ethyl acetate (2 × 50 ml), the combined organic extracts were dried over
sodium sulfate and concentrated in vacuo to afford 354 mg (64%) of 2-ethylpyridine-3-
carboxylic acid (EV-AY8835-001) as an off-white powder. LCMS (method D): retention time




[00364] HATU (224 mg, 0.59 mmol) and DIPEA (103 µl, 0.59 mmol) were added to a
solution of 2-ethylpyridine-3-carboxylic acid (EV-AY8835-001, 77 mg, 0.51 mmol) in DMF (3
ml) and the resulting mixture was stirred at room temperature for 10 minutes. Tert-butyl N-
[(1R,4R,7R)-2-[3-amino-5-methoxy-4-(methylamino)benzoyl]-2-azabicyclo[2.2.1]heptan-7-
yl]carbamate (EV-AY8858-001 synthesised according to Scheme 5, 200 mg, 0.51 mmol) was
added and the reaction mixture was stirred at room temperature for 24h. The reaction mixture
was concentrated in vacuo, dissolved in acetic acid (3 ml) and stirred at 80°C for 4h. The
reaction mixture was concentrated in vacuo and the resulting residue was purified by preparative
HPLC (basic method) to afford 153 mg (59%) of tert-butyl N-[(1R,4R,7R)-2-[2-(2-ethylpyridin-
3-yl)-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-7-
yl]carbamate (EV-AY8830-002) as an off-white powder. LCMS (method D): retention time
1.10min, M/z = 506 (M + 1).
[00365] (1R,4R,7R)-2-[2-(2-Ethylpyridin-3-yl)-7-methoxy-1-methyl-1H-1,3-benzodiazole-
5-carbonyl]-2-azabicyclo[2.2.1]heptan-7-amine hydrochloride, I-96 (EV-AY8837-001) –
Step 4
[00366] 1.25M HCl in ethanol (2 ml) was added to a solution of tert-butyl N-[(1R,4R,7R)-2-
[2-(2-ethylpyridin-3-yl)-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl]-2-
azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AY8830-002, 95 mg, 0.19 mmol) in ethanol (4 ml)
and the resulting mixture was stirred at 50°C for 16h. The reaction mixture was concentrated in
vacuo to afford a white powder. The compound was taken up in methanol (10 ml) and treated
with Smopex-105 (CAS 527751-99-1) metal scavenger (95 mg) and stirred at room temperature
for 2h. The fibres were removed by vacuum filtration and the filtrate concentrated in vacuo to
afford 83 mg (quantitative) of (1R,4R,7R)-2-[2-(2-Ethylpyridin-3-yl)-7-methoxy-1-methyl-1H-
1,3-benzodiazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-7-amine hydrochloride, I-96 (EV-
AY8837-001) as a white powder. LCMS (method H): retention time 2.13min, M/z = 406 (M +
1).




(EOAI3477379) was synthesised according to the procedures described in Scheme 6 via
synthesis of 2-ethyl-5-methoxypyridine-3-carboxylic acid (EV-AY8846-001) as described in
Scheme 6.1
[00370] Scheme 6.1
[00371] 2-Ethyl-5-methoxypyridine-3-carboxylic acid (EV-AY8846-001) – Step 1
[00372] NaOMe (199 mg, 3.69 mmol) was added to a solution of EV-AY8841-001
(synthesised according to Scheme 6, step 1 starting from CAS 1214351-19-5, 208 mg, 1.23
mmol) in DMF (3 ml) and the resulting mixture was stirred at 140°C for 2h. The reaction
mixture was diluted with water (20 ml) and acidified to pH 3 using 5M aqueous HCl solution.
The resulting solution was extracted with ethyl acetate (2 × 100 ml), the combined organic
extracts were dried over sodium sulfate and concentrated in vacuo to afford 190 mg (85%) of 2-
ethyl-5-methoxypyridine-3-carboxylic acid (EV-AY8846-001) as an off-white powder. LCMS
(method D): retention time 0.37min, M/z = 182 (M + 1).





(EOAI3477016) were synthesised according to the procedures described in Scheme 6 via
synthesis of methyl 2-chloro-6-methoxypyridine-3-carboxylate (EV-AY8827-002) as described
in Scheme 6.2.
[00375] Scheme 6.2





(11.0 g, 39.8 mmol) and methyl iodide (3.77 ml, 60.5 mmol) were added to
a solution of 2-chloro-6-oxo-1,6-dihydropyridine-3-carboxylic acid (CAS 1805670-73-8, 3.00 g,
17.3 mmol) in chloroform (30 ml) and the resulting mixture was stirred at 50°C for 3h. The
reaction mixture was filtered under vacuum (washing with chloroform) and the filtrate was
concentrated in vacuo. The residue was purified by flash column chromatography (0-100% ethyl
acetate/heptane) to afford 2.42 g (69%) of methyl 2-chloro-6-methoxypyridine-3-carboxylate





(EOAI3478068) was synthesised according to the procedures described in Scheme 6 via
synthesis of methyl 2-(cyclopropylmethyl)pyridine-3-carboxylate (EV-AZ9626-002) as
described in Scheme 6.3.
[00 Scheme 6.3
[00381] Methyl 2-(prop-2-en-1-yl)pyridine-3-carboxylate (EV-AZ9622-002) – Step 1
[00382] CsF (26.6 g, 174.8 mmol), 4,4,5,5-tetramethyl-2-(prop-2-en-1-yl)-1,3,2-
dioxaborolane (CAS 72824-04-5, 22.01 ml, 116.6 mmol) and Pd(dppf)Cl
2
(4.26 g, 5.83 mmol)
were added to a solution of methyl 2-chloropyridine-3-carboxylate (CAS 2942-59-8, 7.61 ml,
58.3 mmol) in acetonitrile (750 ml) and the resulting mixture was stirred under nitrogen at 70°C
for 1h. A thick precipitate formed. The reaction mixture was diluted with water (300 ml) and
extracted with ethyl acetate (3 × 500 ml). The combined organic extracts were dried over sodium
sulfate, concentrated in vacuo and purified by flash column chromatography (0-80% ethyl
acetate/heptane) to obtain 10.31 g (quantitative) of methyl 2-(prop-2-en-1-yl)pyridine-3-
carboxylate (EV-AZ9622-002) as a yellow volatile oil. LCMS (method D): retention time
0.88min, M/z = 178 (M + 1).
[00383] Methyl 2-(cyclopropylmethyl)pyridine-3-carboxylate (EV-AZ9626-002) – Step 2
[00384] Trifluoroacetic acid (8.64 ml, 112.9 mmol) in DCM (50 ml) was added dropwise to a
solution of 1 M diethylzinc in heptane (112.9 ml) in DCM (150 ml) at 0°C and the resulting
mixture was stirred at 0°C for 10 minutes. Diiodomethane (9.08 ml, 112.9 mmol) was added to
the reaction mixture and stirring at 0°C was continued for 10 minutes. Methyl 2-(prop-2-en-1-
yl)pyridine-3-carboxylate (EV-AZ9622-002, 10 g, 56.4 mmol) in DCM (100 ml) was added
dropwise and the resulting mixture was allowed to reach room temperature over a period of 3h.
The reaction was quenched by addition of water (100 ml) and the organic layer was separated.
The aqueous mixture was re-extracted with DCM (3 × 150 ml). The combined organic extracts
were dried over sodium sulfate, concentrated in vacuo and purified by flash column
chromatography (0-100% ethyl acetate/heptane) to afford 8.26 g (76%) of methyl 2-
(cyclopropylmethyl)pyridine-3-carboxylate (EV-AZ9626-002) as a yellow volatile oil. LCMS




(EOAI3694082) was synthesised according to the procedures described in Scheme 6 via
synthesis of methyl 2-(cyclopropylmethyl)-6-fluoropyridine-3-carboxylate (EV-AZ9632-002) as
described in Scheme 6.4.
[00387] Scheme 6.4




(6.87 g, 47.06 mmol) was added to a solution of methyl 2-
(cyclopropylmethyl)pyridine-3-carboxylate (EV-AZ9626-002, synthesised according to Scheme
6.3, 3.00 g, 15.7 mmol) in acetonitrile (25 ml) and the resulting mixture was stirred at room
temperature for 16h. The reaction mixture was filtered under vacuum and the filtrate
concentrated in vacuo to afford an orange oil which was purified by flash column
chromatography (0-80% ethyl acetate/heptane) to obtain 1.99 g (61%) of methyl 2-
(cyclopropylmethyl)-6-fluoropyridine-3-carboxylate (EV-AZ9632-002) as a colourless volatile




AZ9628-002 (EOAI3689043) was synthesised according to the procedures described in Scheme
6 via synthesis of 2-(cyclopropylmethyl)-6-methoxypyridine-3-carboxylic acid (EV-AZ9615-
002) as described in Scheme 6.5.
[00392] Scheme 6.5
[00393] 2-(Cyclopropylmethyl)-6-methoxypyridine-3-carboxylic acid (EV-AZ9615-002) –
Step 1
[00394] Methanol (35 µl, 0.86 mmol) and tBuOK (97 mg, 0.86 mmol) were added to a
solution of methyl 2-(cyclopropylmethyl)-6-fluoropyridine-3-carboxylate (EV-AZ9632-00
synthesised according to Scheme 6.4, 150 mg, 0.72 mmol) in THF (2 ml) and the resulting
mixture was stirred at room temperature for 2h. The reaction mixture was diluted with water (20
ml) and acidified to pH 4 using 2M aqueous HCl. The resultant solution was extracted with ethyl
acetate (2 × 50 ml), the combined organic extracts were dried over sodium sulfate and
concentrated in vacuo to afford a colourless oil. The residue was dissolved in methanol (5 ml)
and 1 M aqueous NaOH (2.15 ml) was added. The mixture was stirred at 60°C for 3h, diluted
with water (20 ml) and acidified to pH 3 using 2 M aqueous HCl. The resulting solution was
extracted with ethyl acetate (2 × 50 ml), the combined organic extracts were dried over sodium
sulfate and concentrated in vacuo to afford 129 mg (82%) of 2-(cyclopropylmethyl)-6-
methoxypyridine-3-carboxylic acid (EV-AZ9615-002) as an off-white powder. LCMS (method




EV-AZ9655-001 (EOAI3694317) was synthesised according to the procedures described in
Scheme 6 via synthesis of methyl 2-[2-(cyclopropylmethyl)-6-(morpholin-4-yl)pyridin-3-yl]-7-
methoxy-1-methyl-1H-1,3-benzodiazole-5-carboxylate (EV-AZ9651-002) as described in
[00398] Methyl 2-[2-(cyclopropylmethyl)-6-(morpholin-4-yl)pyridin-3-yl]-7-methoxy-1-
methyl-1H-1,3-benzodiazole-5-carboxylate (EV-AZ9651-002) – Step 1
[00399] DIPEA (130 µl, 0.73 mmol) and morpholine (63 µl, 0.73 mmol) were added to a
stirred solution of methyl
2‐[2‐(cyclopropylmethyl)‐6‐fluoropyridin‐3‐yl]‐7‐methoxy‐1‐methyl‐1H‐1,3‐benzodiazole‐5‐car
boxylate (EV-AZ9645-002 synthesised according to Scheme 6.4 and Scheme 1, 90%, 200 mg,
0.49 mmol) in DMSO (2 ml) and the resulting mixture was stirred at 100°C for 2h. Acetonitrile
(1 ml) was added to the reaction mixture and the resulting solution was purified by prep HPLC
(basic method) to afford 161 mg (76%) of methyl 2-[2-(cyclopropylmethyl)-6-(morpholin-4-
yl)pyridin-3-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carboxylate (EV-AZ9651-002) as




AZ9658-002 (EOAI3702812) was synthesised according to the procedures described in Scheme
6 via synthesis of tert-butyl N-[(1R,4R,7R)-2-{2-[6-cyano-2-(cyclopropylmethyl)pyridin-3-yl]-
7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-




yl]carbamate (EV-AZ9657-002) – Step 1
[00404] KCN (38 mg, 0.58 mmol) was added to a solution of tert‐butyl
N‐[(1R,4R,7R)‐2‐{2‐[2‐(cyclopropylmethyl)‐6‐fluoropyridin‐3‐yl]‐7‐methoxy‐1‐methyl‐1H‐1,3‐
benzodiazole‐5‐carbonyl}‐2‐azabicyclo[2.2.1]heptan‐7‐yl]carbamate (EV-AZ9643-002
synthesised according to Scheme 6.5 and Scheme 1, 80 mg, 0.15 mmol) in DMF (2 ml) and the
resulting mixture was stirred at 120°C for 16h. The reaction mixture was diluted with ethyl
acetate (50 ml) and washed with water (2 × 25 ml). The combined organic extracts were dried
over sodium sulfate and concentrated in vacuo to afford a yellow oil. The residue was purified by
prep HPLC (basic method) to afford 58 mg (72%) of tert-butyl N-[(1R,4R,7R)-2-{2-[6-cyano-2-
(cyclopropylmethyl)pyridin-3-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-
azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AZ9657-002) as an off- white powder. LCMS




EV-AZ9624-001 (EOAI3669062) was synthesised according to the procedures described in
Scheme 6 via synthesis of methyl 2-({2-[(tert-butoxy)carbonyl]cyclopropyl}methyl)pyridine-3-
carboxylate (EV-AZ9605-002) described in Scheme 6.8.
[00407] Scheme 6.8
[00408] Methyl 2-({2-[(tert-butoxy)carbonyl]cyclopropyl}methyl)pyridine-3-carboxylate
(EV-AZ9605-002) – Step 1
[00409] Cu(OTf)
2
(0.18 g, 0.51 mmol) and tert-butyl diazoacetate (CAS 35059-50-8, 1.95 ml,
12.7 mmol) were added to a solution of methyl 2‐(prop‐2‐en‐1‐yl)pyridine‐3‐carboxylate (EV-
AZ9622-002 synthesised according to Scheme 6.3, step 1, 90%, 1.00 g, 5.08 mmol) in HFIP (10
ml) at 0°C and the resulting mixture was stirred at room temperature for 2h. The reaction mixture
was quenched with saturated aqueous ammonium chloride (50 ml) and extracted with DCM (2 ×
100 ml). The combined organic extracts were dried over sodium sulfate, concentrated in vacuo
and purified by flash column chromatography (0-80% ethyl acetate/heptane) to afford 1.23 g
(81%) of methyl 2-({2-[(tert-butoxy)carbonyl]cyclopropyl}methyl)pyridine-3-carboxylate (EV-













(85%, 932 mg, 4.55 mmol) were added to a solution of tert-butyl N-[(1R,4R,7R)-2-[3-
methoxy-4-(methylamino)-5-nitrobenzoyl]-2-azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-
AX9493-002 synthesised as in Scheme 5, 85%, 750 mg, 1.52 mmol) in ethanol (5 ml) and water
(3 ml) and the resulting mixture was stirred at 90°C for 4h. The reaction mixture was filtered
under vacuum and the filtrate concentrated in vacuo. The resulting residue was purified by prep
HPLC (basic method) to obtain 360 mg (43%) of tert-butyl N-[(1R,4R,7R)-2-[2-(2-
bromopyridin-3-yl)-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl]-2-
azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AX9488-002) as an off-white powder. LCMS
(method D): retention time 1.13min, M/z = 556, 558 (M + 1).
[00413] (1R,4R,7R)-2-[2-(2-Bromopyridin-3-yl)-7-methoxy-1-methyl-1H-1,3-
benzodiazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-7-amine hydrochloride, I-90, (EV-
AY8802-001) – Step 2
[00414] 1.25M HCl in ethanol (2 ml) was added to a solution of tert-butyl N-[(1R,4R,7R)-2-
[2-(2-bromopyridin-3-yl)-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl]-2-
azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AX9488-002, 105 mg, 0.19 mmol) in ethanol (4
ml) and the resulting mixture was stirred at 5 °C for 5h. The reaction mixture was concentrated
in vacuo to afford a white powder. The compound was taken up in methanol (10 ml) and treated
with Smopex-105 (CAS 527751-99-1) metal scavenger (105 mg) and stirred at room temperature
for 2h. The fibres were removed by vacuum filtration and the filtrate concentrated in vacuo to
afford 93 mg (quantitative) of (1R,4R,7R)-2-[2-(2-bromopyridin-3-yl)-7-methoxy-1-methyl-1H-
1,3-benzodiazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-7-amine hydrochloride, I-90, (EV-
AY8802-001) as a white powder. LCMS (method H): retention time 2.14min, M/z = 457 (M +
1).



















[00416] Compounds of the present invention were assayed as inhibitors of PAD4 using the
assay protocol described below.
[00417] Compounds were solubilised in 100% DMSO to achieve 100 mM final compound
concentration. Compound stock solutions were stored at RT. A series of dilutions were prepared
in DMSO and mixed 8 times with 20 µL mixing volume. Final assay conditions were as
follows:
Reaction volume: 20 µ l
Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2
Final concentrations:
-100 nM hPAD4 enzyme
-50 µM (8-fold sub-Km) substrate peptide
-0.5% DMSO
Total incubation time: 65 mins at 37 °C
Stop solution: 40 µ l 5% TCA in ACN
0.25 µ L of compound solution was added to 10 µ L of 200 nM PAD4 in assay buffer (100 mM
Tris-HCl pH 7.6, 2 mM DTT). After 5 mins, 10 µL of 100 µ M of substrate in buffer (100 mM
Tris-HCl pH 7.6, 2 mM DTT, 2 mM CaCl2) was added and the reaction incubated for 60 mins at
37 ºC. The enzymatic reaction was quenched by addition of 40 µ l of 5% TCA in ACN (1.7%
TCA final concentration) stop solution. Arginine containing substrate and citrulline containing
product (+1 Da mass shift) were subjected to solid phase extraction on Agilent RapidFire (RF)
300 system and detected on a coupled, triple quadrupole Agilent 6460 QQQ mass spectrometry
(MS) device under application of multiple reaction monitoring (MRM) for quantitation.
[00418] Table 2, below, shows the activity of selected compounds of this invention in the
PAD4 assays described above. The compound numbers correspond to the compound numbers in
Table 1. Compounds having an activity designated as “A” provided an IC50 < 1 µM; compounds
having an activity designated as “B” provided an IC5 0 of 1.0 – 5.0 µM; compounds having an
activity designated as “C” provided an IC5 0 of 5.0 – 10.0 µM; and compounds having an activity
designated as “D” provided an IC50 of > 10.0 µM. The term pIC50 = -log(IC50). Compounds
having an activity designated as “E” provided a pIC50 < 4; compounds having an activity
designated as “F” provided a pIC50 of 4.0 – 5.0; compounds having an activity designated as
“G” provided a pIC50 of 5.0-6.0; and compounds having an activity designated as ”H” provided
a pIC50 > 6. “NA” stands for “not assayed.”





1. A compound of formula I’:
I’
or a pharmaceutically acceptable salt thereof, wherein:
Rin A is
4 groups selected from fluorine, -CN, -OR, or C1-6 aliphatic optionally substituted with 1-3
fluorine atoms;
Ring B is a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from
nitrogen, oxygen, or sulfur;
R1 is hydrogen, -Cy, or C1-6 aliphatic optionally substituted with –Cy and optionally further
substituted with 1-4 groups selected from fluorine, -CN, or -OR;
each -Cy is independently a 6-membered aryl ring containing 0-2 nitrogen atoms, or a 4-7
membered saturated monocyclic ring having 0-2 heteroatoms independently selected from
nitrogen, oxygen, or sulphur, wherein –Cy is optionally substituted with 1-4 groups selected
from fluorine, -CN, or -OR;
R2 is hydrogen, -CN, -OR, -Cy, or C1-10 aliphatic optionally substituted with –Cy and optionally
further substituted with 1-5 groups selected from fluorine, –CN, or –OR; or:
two R2 groups on the same carbon are optionally taken together to form =O;
n is 1, 2, or 3;
X 1 is N or C(R 3 );
R3 is –R, halogen, or –OR;
each R is independently hydrogen or C1-6 aliphatic optionally substituted with 1-3 fluorine
atoms;
L is selected from a covalent bond or a C1-6 membered straight or branched, saturated or
unsaturated hydrocarbon chain wherein one methylene unit of L is optionally replaced by –
S(O) 2 – or –C(O)N(R y )-, wherein Ry is R or –CH 2 phenyl; and
R4 is halogen, R, phenyl, or a 5-6-membered heteroaryl ring having 1-3 heteroatoms
independently selected from nitrogen, oxygen, or sulphur, wherein R4 is optionally substituted
with 1-4 groups independently selected from halogen, -CN, -OR, -C(O)OH, or C1-6 aliphatic
optionally substituted with 1-3 fluorine atoms.
2. The compound according to claim 1, wherein said compound is of formula I’-a:
I’-a
or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 1, wherein said compound is of formula I’-b:
I’-b
or a pharmaceutically acceptable salt thereof.
4. The compound according to any of claims 1 through 3, wherein Ring A is ,
6. The compound according to any of claims 1 through 5, wherein Ring B is a 6-membered
heteroaryl ring having 1-2 nitrogens.
7. The compound according to any of claims 1 through 5, wherein Ring B is a 5-membered
heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
8. The compound according to claim 6, wherein Ring B is pyridyl.
9. The compound according to claim 7, wherein Ring B is imidazolyl, pyrazolyl, pyrrolyl,
or thiazolyl.
10. The compound according to claim 9, wherein Ring B is pyrrolyl.
11. The compound according to any of claims 1 through 10, wherein R4 is phenyl or pyridyl.
12. The compound according to claim 1, wherein said compound is selected from those
depicted in Table 1.
13. A pharmaceutically acceptable composition comprising the compound according to any
of claims 1 through 12, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
14. The composition according to claim 13, in combination with an additional therapeutic
agent.
15. A method of inhibiting PAD4 in a subject or in a biological sample comprising the step
of contacting the PAD4 with a compound according to any of claims 1 through 12.
16. A method of treating a PAD4-mediated disease, disorder, or condition in a subject in
need thereof comprising the step of administering to said subject the composition according to
claim 13.
17. The method according to claim 16, wherein said subject is a human subject.
18. The method according to claim 16, wherein said subject is a veterinary subject.
19. The method according to claim 16, wherein the PAD4-mediated disease, disorder, or
condition is selected from the group consisting of acid-induced lung injury, acne (PAPA), acute
lymphocytic leukemia, acute, respiratory distress syndrome, Addison’s disease, adrenal
hyperplasia, adrenocortical insufficiency, ageing, AIDS, alcoholic hepatitis, alcoholic hepatitis,
alcoholic liver disease, allergen induced asthma, allergic bronchopulmonary, aspergillosis,
allergic conjunctivitis, alopecia, Alzheimer’s disease, amyloidosis, amyotropic lateral sclerosis,
and weight loss, angina pectoris, angioedema, anhidrotic ecodermal dysplasia-ID, ankylosing
spondylitis, anterior segment, inflammation, antiphospholipid syndrome, aphthous stomatitis,
appendicitis, arthritis, asthma, atherosclerosis, atopic dermatitis, autoimmune diseases,
autoimmune hepatitis, bee sting-induced inflammation, behcet’s disease, Behcet’s syndrome,
Bells Palsey, berylliosis, Blau syndrome, bone pain, bronchiolitis, burns, bursitis, cancer, cardiac
hypertrophy, carpal tunnel syndrome, catabolic disorders, cataracts, cerebral aneurysm, chemical
irritant-induced inflammation, chorioretinitis, chronic heart failure, chronic lung disease of
prematurity, chronic lymphocytic leukemia, chronic obstructive pulmonary disease, colitis,
complex regional pain syndrome, connective tissue disease, corneal ulcer, crohn’s disease,
cryopyrin-associated periodic syndromes, cyrptococcosis, cystic fibrosis, deficiency of the
interleukin-1–receptor antagonist (DIRA), dermatitis, dermatitis endotoxemia, dermatomyositis,
diffuse intrinsic pontine glioma, endometriosis, endotoxemia, epicondylitis, erythroblastopenia,
familial amyloidotic polyneuropathy, familial cold urticarial, familial mediterranean fever, fetal
growth retardation, glaucoma, glomerular disease, glomerular nephritis, gout, gouty arthritis,
graft-versus-host disease, gut diseases, head injury, headache, hearing loss, heart disease,
hemolytic anemia, Henoch-Scholein purpura, hepatitis, hereditary periodic fever syndrome,
herpes zoster and simplex, HIV-1, Hodgkin’s disease, Huntington’s disease, hyaline membrane
disease, hyperammonemia, hypercalcemia, hypercholesterolemia, hyperimmunoglobulinemia D
with recurrent fever (HIDS), hypoplastic and other anemias, hypoplastic anemia, idiopathic
thrombocytopenic purpura, incontinentia pigmenti, infectious mononucleosis, inflammatory
bowel disease, inflammatory lung disease, inflammatory neuropathy, inflammatory pain, insect
bite-induced inflammation, iritis, irritant-induced inflammation, ischemia/reperfusion, juvenile
rheumatoid arthritis, keratitis, kidney disease, kidney injury caused by parasitic infections,
kidney injury caused by parasitic infections, kidney transplant rejection prophylaxis,
leptospiriosis, leukemia, Loeffler’s syndrome, lung injury, lung injury, lupus, lupus, lupus
nephritis, lymphoma, meningitis, mesothelioma, mixed connective tissue disease, Muckle-Wells
syndrome (urticaria deafness amyloidosis), multiple sclerosis, muscle wasting, muscular
dystrophy, myasthenia gravis, myocarditis, mycosis fungiodes, mycosis fungoides,
myelodysplastic syndrome, myositis, nasal sinusitis, necrotizing enterocolitis, neonatal onset
multisystem inflammatory disease (NOMID), nephrotic syndrome, neuritis, neuropathological
diseases, non-allergen induced asthma, obesity, ocular allergy, optic neuritis, organ transplant,
osterarthritis, otitis media, paget’s disease, pain, pancreatitis, Parkinson’s disease, pemphigus,
pericarditis, periodic fever, periodontitis, peritoneal endometriosis, pertussis, pharyngitis and
adenitis (PFAPA syndrome), plant irritant-induced inflammation, pneumonia, pneumonitis,
pneumosysts infection, poison ivy/ urushiol oil-induced inflammation, polyarteritis nodosa,
polychondritis, polycystic kidney disease, polymyositis, psoriasis, psoriasis, psoriasis, psoriasis,
psychosocial stress diseases, pulmonary disease, pulmonary hypertension, pulmonayr fibrosis,
pyoderma gangrenosum, pyogenic sterile arthritis, renal disease, retinal disease, rheumatic
carditis, rheumatic disease, rheumatoid arthritis, sarcoidosis, seborrhea, sepsis, severe pain,
sickle cell, sickle cell anemia, silica-induced disease, Sjogren’s syndrome, skin diseases, sleep
apnea, solid tumors, spinal cord injury, Stevens-Johnson syndrome, stroke, subarachnoid
hemorrhage, sunburn, temporal arteritis, tenosynovitis, thrombocytopenia, thyroiditis, tissue
transplant, TNF receptor associated periodic syndrome (TRAPS), toxoplasmosis, transplant,
traumatic brain injury, tuberculosis, type 1 diabetes, type 2 diabetes, ulcerative colitis, urticarial,
uveitis, and Wegener’s granulomatosis.
20. The method according to claim 16, wherein the PAD4-mediated disease, disorder, or
condition is selected from rheumatoid arthritis, vasculitis, systemic lupus erythematosus,
ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.
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